Note 1. Basis of presentation and summary of significant accounting policies
\n\u00a0
\nThe accompanying unaudited\u00a0interim consolidated financial statements reflect the accounts of the Company for the quarterly period ended November 30, 2024\u00a0(the \u201cFinancial Statements\u201d). The Financial Statements were prepared in accordance with generally accepted accounting principles in the United States of America (\u201cU.S. GAAP\u201d) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (\u201cSEC\u201d) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP and should be read in conjunction with the audited consolidated financial statements (the \u201cAnnual Financial Statements\u201d) included in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\u00a0 May 31, 2024\u00a0(the \u201cAnnual Report\u201d). These\u00a0Financial Statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full fiscal year.\u00a0
\n\u00a0
\nThese Financial Statements have been prepared on a\u00a0going concern basis, which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company\u2019s accounting policies.
\n\u00a0
\nAll amounts in the Financial Statements, notes and tables have been rounded to the nearest thousand, except par values and per share amounts, and unless otherwise indicated.
\n\u00a0
\nCertain items of the comparative figures have been changed to conform to the presentation adopted in the current period. In limited cases, certain line items that were previously aggregated have been disaggregated within the Consolidated Statements of Cash Flows for the periods presented.
\n\u00a0
\nBasis of consolidation
\n\u00a0
\nSubsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of all subsidiaries are included in the Financial Statements from the date that control commences until the date that control ceases. All intercompany balances and transactions have been eliminated on consolidation. A complete list of our subsidiaries that existed as of our most recent fiscal year end is included in the Annual Report.
\n\u00a0
\nImpairment of goodwill and indefinite-lived intangible assets
\n\u00a0
\nGoodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently when events or circumstances indicate that impairment may have occurred. As part of the impairment evaluation, we may elect to perform an assessment of qualitative factors. If this qualitative assessment indicates that it is more likely than not that the fair value of the indefinite-lived intangible asset or the reporting unit (for goodwill) is less than its carrying value, a quantitative impairment test to compare the fair value to the carrying value is performed. An impairment charge is recorded if the carrying value exceeds the fair value. The assessment of whether an indication of impairment exists is performed at the end of each reporting period and requires the application of judgment, historical experience, and external and internal sources of information. We make estimates in determining the future cash flows and discount rates in the quantitative impairment test to compare the fair value to the carrying value.
\n\u00a0
\nDuring the quarter, the Company identified an indicator of impairment with respect to its cannabis and beverage reporting units and performed an interim impairment test, and determined\u00a0that the fair value of these reporting units was greater than their carrying amounts and thus impairment expense was recognized. Within the beverage reporting unit, a reasonably possible change in any of the inputs within the determination of fair value would\u00a0not\u00a0result in a material change to this determination of no\u00a0impairment expense recognized during the period ended November 30, 2024. Within the cannabis reporting unit, a key input into the determination of fair value is estimated probabilities associated with legalization of cannabis within the United States and internationally.\u00a0 Changes to those probabilities resulting in continued delays in legalization of cannabis within the United States and internationally, or adverse regulatory changes to existing legislation, could have an unfavorable impact on the estimated future cash flows, and ultimately, the fair value of the cannabis reporting unit, which may\u00a0result in a material change to the determination of no impairment expense recognized in future reporting periods.
\n\u00a0
\nConvertible notes receivable
\n\u00a0
\nConvertible notes receivable\u00a0includes various investments in which the Company has the right, or potential right to convert the indenture into Common Stock of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the consolidated statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than not that we will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of loss and the remaining amount is recorded in other comprehensive income (loss).
\n\u00a0
\n \n \nEarnings (loss) per share
\n\u00a0
\nBasic earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the year. Diluted earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of Common Stock outstanding under the\u00a0share lending\u00a0arrangement entered into in conjunction with the TLRY\u00a027 Notes, see Note\u00a013\u00a0(Convertible debentures payable) are excluded from the calculation of basic and diluted earnings per share\u00a0because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.\u00a0
\n\u00a0
\nIn computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the three\u00a0months ended\u00a0 November 30, 2024 and\u00a0 November 30, 2023, the dilutive potential common share equivalents outstanding consisted of the following: 23,365,351 and 20,939,082 common shares from RSUs, 3,060,318 and 6,280,065 common shares from share options, 6,209,000 and 6,209,000 common shares for warrants and 58,757,057 and 77,181,260 common shares for convertible debentures, respectively.
\n\u00a0
\nRecently issued\u00a0accounting pronouncements not yet adopted\u00a0
\n\u00a0
\nIn August 2023, the Financial Accounting Standards Board (\"FASB\") issued Accounting Standards Update (\"ASU\") 2023-05, Business Combination - Joint Venture Formations (Subtopic 805-60) Recognition and Initial Measurement (\u201cASU 2023-05\u201d), which is intended to address the accounting for contributions made to a joint venture. ASU 2023-05 is effective for the Company beginning June 1, 2026. This update will be applied prospectively and the Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\nIn October\u00a02023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC\u2019s Disclosure Update and Simplification Initiative,\u00a0which amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification (the \u201cCodification\u201d). The effective date for each amendment will be the date on which the SEC\u2019s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity.\u00a0The Company is currently evaluating the effect of adopting this ASU.\u00a0
\n\u00a0
\nIn November\u00a02023, the FASB issued ASU 2023-07,\u00a0Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures,\u00a0which requires public entities to disclose information about their reportable segments, including\u00a0segments' significant expenses on an interim and annual basis.\u00a0ASU 2023-07 is effective for the Company beginning with its\u00a0fiscal year ended May 31, 2025 and will be disclosed retrospectively\u00a0in the Financial\u00a0Statements\u00a0on Form 10-K filed with the SEC for such period.\u00a0The Company is in the process of evaluating the impact of the financial statement disclosure requirements.
\n\u00a0
\nIn\u00a0 December 2023,\u00a0the FASB issued ASU\u00a02023-09,\u00a0Income Taxes (Topic\u00a0740)\u00a0Improvements to Income Tax Disclosures,\u00a0which requires public entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis. ASU\u00a02023-09\u00a0is effective for the Company\u00a0beginning\u00a0 June 1, 2025.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\nIn November 2024, the FASB issued ASU 2024-03,\u00a0Income Statement\u2014Reporting Comprehensive Income\u2014Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,\u00a0which requires disaggregated disclosure of income statement expenses for public business entities. ASU 2024-03\u00a0is effective for the Company beginning June 1, 2025.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\nIn November 2024, the FASB issued ASU 2024-04,\u00a0Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments,\u00a0which seeks to clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for the Company beginning June 1, 2025.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-779","factDimensions":{"xbrl:concept":"us-gaap:BasisOfAccountingPolicyPolicyTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Basis of consolidation
\n\u00a0
\nSubsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of all subsidiaries are included in the Financial Statements from the date that control commences until the date that control ceases. All intercompany balances and transactions have been eliminated on consolidation. A complete list of our subsidiaries that existed as of our most recent fiscal year end is included in the Annual Report.
\n\u00a0
"}]},{"name":"rpt:f-780","factDimensions":{"xbrl:concept":"us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Impairment of goodwill and indefinite-lived intangible assets
\n\u00a0
\nGoodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently when events or circumstances indicate that impairment may have occurred. As part of the impairment evaluation, we may elect to perform an assessment of qualitative factors. If this qualitative assessment indicates that it is more likely than not that the fair value of the indefinite-lived intangible asset or the reporting unit (for goodwill) is less than its carrying value, a quantitative impairment test to compare the fair value to the carrying value is performed. An impairment charge is recorded if the carrying value exceeds the fair value. The assessment of whether an indication of impairment exists is performed at the end of each reporting period and requires the application of judgment, historical experience, and external and internal sources of information. We make estimates in determining the future cash flows and discount rates in the quantitative impairment test to compare the fair value to the carrying value.
\n\u00a0
\nDuring the quarter, the Company identified an indicator of impairment with respect to its cannabis and beverage reporting units and performed an interim impairment test, and determined\u00a0that the fair value of these reporting units was greater than their carrying amounts and thus impairment expense was recognized. Within the beverage reporting unit, a reasonably possible change in any of the inputs within the determination of fair value would\u00a0not\u00a0result in a material change to this determination of no\u00a0impairment expense recognized during the period ended November 30, 2024. Within the cannabis reporting unit, a key input into the determination of fair value is estimated probabilities associated with legalization of cannabis within the United States and internationally.\u00a0 Changes to those probabilities resulting in continued delays in legalization of cannabis within the United States and internationally, or adverse regulatory changes to existing legislation, could have an unfavorable impact on the estimated future cash flows, and ultimately, the fair value of the cannabis reporting unit, which may\u00a0result in a material change to the determination of no impairment expense recognized in future reporting periods.
\n\u00a0
"}]},{"name":"rpt:f-781","factDimensions":{"xbrl:concept":"us-gaap:FinanceLoansAndLeasesReceivablePolicy","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Convertible notes receivable
\n\u00a0
\nConvertible notes receivable\u00a0includes various investments in which the Company has the right, or potential right to convert the indenture into Common Stock of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the consolidated statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than not that we will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of loss and the remaining amount is recorded in other comprehensive income (loss).
\n\u00a0
"}]},{"name":"rpt:f-782","factDimensions":{"xbrl:concept":"us-gaap:EarningsPerSharePolicyTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Earnings (loss) per share
\n\u00a0
\nBasic earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the year. Diluted earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of Common Stock outstanding under the\u00a0share lending\u00a0arrangement entered into in conjunction with the TLRY\u00a027 Notes, see Note\u00a013\u00a0(Convertible debentures payable) are excluded from the calculation of basic and diluted earnings per share\u00a0because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.\u00a0
\n\u00a0
\nIn computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the three\u00a0months ended\u00a0 November 30, 2024 and\u00a0 November 30, 2023, the dilutive potential common share equivalents outstanding consisted of the following: 23,365,351 and 20,939,082 common shares from RSUs, 3,060,318 and 6,280,065 common shares from share options, 6,209,000 and 6,209,000 common shares for warrants and 58,757,057 and 77,181,260 common shares for convertible debentures, respectively.
\n\u00a0
"}]},{"name":"rpt:f-783","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2024-09-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"23365351"}]},{"name":"rpt:f-784","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"20939082"}]},{"name":"rpt:f-785","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2024-09-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"3060318"}]},{"name":"rpt:f-786","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"6280065"}]},{"name":"rpt:f-787","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2024-09-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:WarrantsMember"},"factValues":[{"value":"6209000"}]},{"name":"rpt:f-788","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:WarrantsMember"},"factValues":[{"value":"6209000"}]},{"name":"rpt:f-789","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities","xbrl:period":"2024-09-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"58757057"}]},{"name":"rpt:f-790","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"77181260"}]},{"name":"rpt:f-791","factDimensions":{"xbrl:concept":"us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Recently issued\u00a0accounting pronouncements not yet adopted\u00a0
\n\u00a0
\nIn August 2023, the Financial Accounting Standards Board (\"FASB\") issued Accounting Standards Update (\"ASU\") 2023-05, Business Combination - Joint Venture Formations (Subtopic 805-60) Recognition and Initial Measurement (\u201cASU 2023-05\u201d), which is intended to address the accounting for contributions made to a joint venture. ASU 2023-05 is effective for the Company beginning June 1, 2026. This update will be applied prospectively and the Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\nIn October\u00a02023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC\u2019s Disclosure Update and Simplification Initiative,\u00a0which amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification (the \u201cCodification\u201d). The effective date for each amendment will be the date on which the SEC\u2019s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity.\u00a0The Company is currently evaluating the effect of adopting this ASU.\u00a0
\n\u00a0
\nIn November\u00a02023, the FASB issued ASU 2023-07,\u00a0Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures,\u00a0which requires public entities to disclose information about their reportable segments, including\u00a0segments' significant expenses on an interim and annual basis.\u00a0ASU 2023-07 is effective for the Company beginning with its\u00a0fiscal year ended May 31, 2025 and will be disclosed retrospectively\u00a0in the Financial\u00a0Statements\u00a0on Form 10-K filed with the SEC for such period.\u00a0The Company is in the process of evaluating the impact of the financial statement disclosure requirements.
\n\u00a0
\nIn\u00a0 December 2023,\u00a0the FASB issued ASU\u00a02023-09,\u00a0Income Taxes (Topic\u00a0740)\u00a0Improvements to Income Tax Disclosures,\u00a0which requires public entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis. ASU\u00a02023-09\u00a0is effective for the Company\u00a0beginning\u00a0 June 1, 2025.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\nIn November 2024, the FASB issued ASU 2024-03,\u00a0Income Statement\u2014Reporting Comprehensive Income\u2014Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,\u00a0which requires disaggregated disclosure of income statement expenses for public business entities. ASU 2024-03\u00a0is effective for the Company beginning June 1, 2025.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\nIn November 2024, the FASB issued ASU 2024-04,\u00a0Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments,\u00a0which seeks to clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for the Company beginning June 1, 2025.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\n\u00a0
\n "}]},{"name":"rpt:f-792","factDimensions":{"xbrl:concept":"us-gaap:InventoryDisclosureTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 2. Inventory
\n\u00a0
\nInventory consisted of the following:
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Beverage inventory | \u00a0 | \u00a0 | 70,817 | \u00a0 | \u00a0 | $ | 52,831 | \u00a0 |
| Cannabis plants | \u00a0 | \u00a0 | 14,320 | \u00a0 | \u00a0 | \u00a0 | 13,828 | \u00a0 |
| Dried cannabis | \u00a0 | \u00a0 | 100,130 | \u00a0 | \u00a0 | \u00a0 | 108,721 | \u00a0 |
| Cannabis derivatives | \u00a0 | \u00a0 | 6,642 | \u00a0 | \u00a0 | \u00a0 | 4,504 | \u00a0 |
| Cannabis vapes | \u00a0 | \u00a0 | 3,879 | \u00a0 | \u00a0 | \u00a0 | 4,132 | \u00a0 |
| Packaging and other inventory items | \u00a0 | \u00a0 | 17,551 | \u00a0 | \u00a0 | \u00a0 | 22,115 | \u00a0 |
| Distribution inventory | \u00a0 | \u00a0 | 41,024 | \u00a0 | \u00a0 | \u00a0 | 35,645 | \u00a0 |
| Wellness inventory | \u00a0 | \u00a0 | 11,644 | \u00a0 | \u00a0 | \u00a0 | 10,311 | \u00a0 |
| Total | \u00a0 | $ | 266,007 | \u00a0 | \u00a0 | $ | 252,087 | \u00a0 |
\u00a0\u00a0
\n "}]},{"name":"rpt:f-793","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfInventoryCurrentTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Beverage inventory | \u00a0 | \u00a0 | 70,817 | \u00a0 | \u00a0 | $ | 52,831 | \u00a0 |
| Cannabis plants | \u00a0 | \u00a0 | 14,320 | \u00a0 | \u00a0 | \u00a0 | 13,828 | \u00a0 |
| Dried cannabis | \u00a0 | \u00a0 | 100,130 | \u00a0 | \u00a0 | \u00a0 | 108,721 | \u00a0 |
| Cannabis derivatives | \u00a0 | \u00a0 | 6,642 | \u00a0 | \u00a0 | \u00a0 | 4,504 | \u00a0 |
| Cannabis vapes | \u00a0 | \u00a0 | 3,879 | \u00a0 | \u00a0 | \u00a0 | 4,132 | \u00a0 |
| Packaging and other inventory items | \u00a0 | \u00a0 | 17,551 | \u00a0 | \u00a0 | \u00a0 | 22,115 | \u00a0 |
| Distribution inventory | \u00a0 | \u00a0 | 41,024 | \u00a0 | \u00a0 | \u00a0 | 35,645 | \u00a0 |
| Wellness inventory | \u00a0 | \u00a0 | 11,644 | \u00a0 | \u00a0 | \u00a0 | 10,311 | \u00a0 |
| Total | \u00a0 | $ | 266,007 | \u00a0 | \u00a0 | $ | 252,087 | \u00a0 |
Note 3. Capital assets
\n\u00a0
\nCapital assets consisted of the following:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \nNovember 30, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n||
| Land | \n \u00a0 | \n$ | \n44,177 | \n\u00a0 | \n\u00a0 | \n$ | \n45,577 | \n\u00a0 | \n
| Production facilities | \n \u00a0 | \n\u00a0 | \n388,456 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n369,630 | \n\u00a0 | \n
| Equipment | \n \u00a0 | \n\u00a0 | \n257,310 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n258,532 | \n\u00a0 | \n
| Leasehold improvements | \n \u00a0 | \n\u00a0 | \n18,786 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n19,377 | \n\u00a0 | \n
| Finance lease, right-of-use assets | \n \u00a0 | \n\u00a0 | \n41,479 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n43,993 | \n\u00a0 | \n
| Construction in progress | \n \u00a0 | \n\u00a0 | \n13,864 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n10,713 | \n\u00a0 | \n
| \u00a0 | \n\u00a0 | \n$ | \n764,072 | \n\u00a0 | \n\u00a0 | \n$ | \n747,822 | \n\u00a0 | \n
| Less: accumulated amortization | \n \u00a0 | \n\u00a0 | \n(209,653 | \n) | \n\u00a0 | \n\u00a0 | \n(189,575 | \n) | \n
| Total | \n \u00a0 | \n$ | \n554,419 | \n\u00a0 | \n\u00a0 | \n$ | \n558,247 | \n\u00a0 | \n
\u00a0 \u00a0\u00a0
\nAssets held for sale\u00a0consisted of the following:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n May 31, | \n \u00a0 | \n||
| \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n||
| Land | \n \u00a0 | \n$ | \n932 | \n\u00a0 | \n\u00a0 | \n$ | \n954 | \n\u00a0 | \n
| Production facilities | \n \u00a0 | \n\u00a0 | \n24,252 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n24,682 | \n\u00a0 | \n
| Equipment | \n \u00a0 | \n\u00a0 | \n6,299 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n6,438 | \n\u00a0 | \n
| \u00a0 | \n\u00a0 | \n$ | \n31,483 | \n\u00a0 | \n\u00a0 | \n$ | \n32,074 | \n\u00a0 | \n
\u00a0
\nDuring the fiscal year ended\u00a0 May 31, 2024,\u00a0the Company classified the following assets from its Cannabis reporting segment as held for sale, including its\u00a0Quebec cultivation facility, the Fort Collins, CO partially vacant warehouse facility, and the Broken Coast\u00a0former cultivation facility located in Duncan, B.C. Following an\u00a0assessment of facility capacity utilization, it was determined that these facilities would be exited and held for sale.\u00a0It is expected that the sale of these assets\u00a0will be completed within\u00a0twelve\u00a0months from the period in which they were classified as held for sale. Assets held for sale are\u00a0measured at the lower of carrying amount and their fair value less costs to sell, and are\u00a0no\u00a0longer depreciated. Disposition of assets held for sale are recorded in the consolidated statement of\u00a0loss and comprehensive loss, within the line, \u201cNon-operating income (expense), net\u201d.\u00a0
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-813","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \nNovember 30, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n||
| Land | \n \u00a0 | \n$ | \n44,177 | \n\u00a0 | \n\u00a0 | \n$ | \n45,577 | \n\u00a0 | \n
| Production facilities | \n \u00a0 | \n\u00a0 | \n388,456 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n369,630 | \n\u00a0 | \n
| Equipment | \n \u00a0 | \n\u00a0 | \n257,310 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n258,532 | \n\u00a0 | \n
| Leasehold improvements | \n \u00a0 | \n\u00a0 | \n18,786 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n19,377 | \n\u00a0 | \n
| Finance lease, right-of-use assets | \n \u00a0 | \n\u00a0 | \n41,479 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n43,993 | \n\u00a0 | \n
| Construction in progress | \n \u00a0 | \n\u00a0 | \n13,864 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n10,713 | \n\u00a0 | \n
| \u00a0 | \n\u00a0 | \n$ | \n764,072 | \n\u00a0 | \n\u00a0 | \n$ | \n747,822 | \n\u00a0 | \n
| Less: accumulated amortization | \n \u00a0 | \n\u00a0 | \n(209,653 | \n) | \n\u00a0 | \n\u00a0 | \n(189,575 | \n) | \n
| Total | \n \u00a0 | \n$ | \n554,419 | \n\u00a0 | \n\u00a0 | \n$ | \n558,247 | \n\u00a0 | \n
| \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n May 31, | \n \u00a0 | \n||
| \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n||
| Land | \n \u00a0 | \n$ | \n932 | \n\u00a0 | \n\u00a0 | \n$ | \n954 | \n\u00a0 | \n
| Production facilities | \n \u00a0 | \n\u00a0 | \n24,252 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n24,682 | \n\u00a0 | \n
| Equipment | \n \u00a0 | \n\u00a0 | \n6,299 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n6,438 | \n\u00a0 | \n
| \u00a0 | \n\u00a0 | \n$ | \n31,483 | \n\u00a0 | \n\u00a0 | \n$ | \n32,074 | \n\u00a0 | \n
\u00a0Note 4. Leases
\n\u00a0
\nThe table below presents the lease-related assets and liabilities recorded on the balance sheet.
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | Classification on Balance Sheet | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease, right-of-use assets | Capital assets | \u00a0 | $ | 41,479 | \u00a0 | \u00a0 | $ | 43,993 | \u00a0 |
| Operating lease, right-of-use assets | Operating lease, right-of-use assets | \u00a0 | \u00a0 | 18,243 | \u00a0 | \u00a0 | \u00a0 | 16,101 | \u00a0 |
| Total right-of-use asset | \u00a0 | $ | 59,722 | \u00a0 | \u00a0 | $ | 60,094 | \u00a0 | |
| Liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current: | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current portion of finance lease liabilities |
| \u00a0 | $ | 1,495 | \u00a0 | \u00a0 | $ | 1,092 | \u00a0 |
| Current portion of operating lease liabilities |
| \u00a0 | \u00a0 | 5,077 | \u00a0 | \u00a0 | \u00a0 | 3,999 | \u00a0 |
| Non-current: | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities |
| \u00a0 | \u00a0 | 45,028 | \u00a0 | \u00a0 | \u00a0 | 43,948 | \u00a0 |
| Operating lease liabilities |
| \u00a0 | \u00a0 | 16,996 | \u00a0 | \u00a0 | \u00a0 | 16,474 | \u00a0 |
| Total lease liabilities | \u00a0 | $ | 68,596 | \u00a0 | \u00a0 | $ | 65,513 | \u00a0 |
\u00a0
\nThe following table presents the future undiscounted payments associated with lease liabilities as of November 30, 2024:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Operating | \u00a0 | \u00a0 | Finance | \u00a0 | ||
| \u00a0 | \u00a0 | leases | \u00a0 | \u00a0 | leases | \u00a0 | ||
| 2025 | \u00a0 | $ | 3,520 | \u00a0 | \u00a0 | $ | 2,253 | \u00a0 |
| 2026 | \u00a0 | \u00a0 | 6,757 | \u00a0 | \u00a0 | \u00a0 | 4,507 | \u00a0 |
| 2027 | \u00a0 | \u00a0 | 5,778 | \u00a0 | \u00a0 | \u00a0 | 4,507 | \u00a0 |
| 2028 | \u00a0 | \u00a0 | 4,768 | \u00a0 | \u00a0 | \u00a0 | 4,507 | \u00a0 |
| Thereafter | \u00a0 | \u00a0 | 6,604 | \u00a0 | \u00a0 | \u00a0 | 70,750 | \u00a0 |
| Total minimum lease payments | \u00a0 | $ | 27,427 | \u00a0 | \u00a0 | $ | 86,524 | \u00a0 |
| Imputed interest | \u00a0 | \u00a0 | (5,354 | ) | \u00a0 | \u00a0 | (40,001 | ) |
| Obligations recognized | \u00a0 | $ | 22,073 | \u00a0 | \u00a0 | $ | 46,523 | \u00a0 |
\u00a0
\n "}]},{"name":"rpt:f-842","factDimensions":{"xbrl:concept":"tlry:LeaseRelatedAssetsAndLiabilitiesTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | Classification on Balance Sheet | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease, right-of-use assets | Capital assets | \u00a0 | $ | 41,479 | \u00a0 | \u00a0 | $ | 43,993 | \u00a0 |
| Operating lease, right-of-use assets | Operating lease, right-of-use assets | \u00a0 | \u00a0 | 18,243 | \u00a0 | \u00a0 | \u00a0 | 16,101 | \u00a0 |
| Total right-of-use asset | \u00a0 | $ | 59,722 | \u00a0 | \u00a0 | $ | 60,094 | \u00a0 | |
| Liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current: | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current portion of finance lease liabilities |
| \u00a0 | $ | 1,495 | \u00a0 | \u00a0 | $ | 1,092 | \u00a0 |
| Current portion of operating lease liabilities |
| \u00a0 | \u00a0 | 5,077 | \u00a0 | \u00a0 | \u00a0 | 3,999 | \u00a0 |
| Non-current: | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities |
| \u00a0 | \u00a0 | 45,028 | \u00a0 | \u00a0 | \u00a0 | 43,948 | \u00a0 |
| Operating lease liabilities |
| \u00a0 | \u00a0 | 16,996 | \u00a0 | \u00a0 | \u00a0 | 16,474 | \u00a0 |
| Total lease liabilities | \u00a0 | $ | 68,596 | \u00a0 | \u00a0 | $ | 65,513 | \u00a0 |
| \u00a0 | \u00a0 | Operating | \u00a0 | \u00a0 | Finance | \u00a0 | ||
| \u00a0 | \u00a0 | leases | \u00a0 | \u00a0 | leases | \u00a0 | ||
| 2025 | \u00a0 | $ | 3,520 | \u00a0 | \u00a0 | $ | 2,253 | \u00a0 |
| 2026 | \u00a0 | \u00a0 | 6,757 | \u00a0 | \u00a0 | \u00a0 | 4,507 | \u00a0 |
| 2027 | \u00a0 | \u00a0 | 5,778 | \u00a0 | \u00a0 | \u00a0 | 4,507 | \u00a0 |
| 2028 | \u00a0 | \u00a0 | 4,768 | \u00a0 | \u00a0 | \u00a0 | 4,507 | \u00a0 |
| Thereafter | \u00a0 | \u00a0 | 6,604 | \u00a0 | \u00a0 | \u00a0 | 70,750 | \u00a0 |
| Total minimum lease payments | \u00a0 | $ | 27,427 | \u00a0 | \u00a0 | $ | 86,524 | \u00a0 |
| Imputed interest | \u00a0 | \u00a0 | (5,354 | ) | \u00a0 | \u00a0 | (40,001 | ) |
| Obligations recognized | \u00a0 | $ | 22,073 | \u00a0 | \u00a0 | $ | 46,523 | \u00a0 |
Note 5. Intangible Assets
\n\u00a0
\nIntangible assets consisted of the following items:
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Customer relationships & distribution channels | \u00a0 | $ | 597,441 | \u00a0 | \u00a0 | $ | 603,939 | \u00a0 |
| Licenses, permits & applications | \u00a0 | \u00a0 | 364,612 | \u00a0 | \u00a0 | \u00a0 | 368,057 | \u00a0 |
| Non-compete agreements | \u00a0 | \u00a0 | 12,346 | \u00a0 | \u00a0 | \u00a0 | 12,403 | \u00a0 |
| Intellectual property, trademarks, knowhow & brands | \u00a0 | \u00a0 | 602,179 | \u00a0 | \u00a0 | \u00a0 | 608,672 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | 1,576,578 | \u00a0 | \u00a0 | $ | 1,593,071 | \u00a0 |
| Less: accumulated amortization | \u00a0 | \u00a0 | (294,089 | ) | \u00a0 | \u00a0 | (261,758 | ) |
| Less: impairments | \u00a0 | \u00a0 | (415,844 | ) | \u00a0 | \u00a0 | (415,844 | ) |
| Total | \u00a0 | $ | 866,645 | \u00a0 | \u00a0 | $ | 915,469 | \u00a0 |
\u00a0
\nIncluded in licenses, permits & applications was\u00a0$178,387\u00a0of indefinite-lived intangible assets as of November 30, 2024, compared to $182,851\u00a0as of May 31, 2024.
\n\u00a0
\nExpected future amortization expense for intangible assets as of\u00a0 November 30, 2024\u00a0is\u00a0as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Amortization | \u00a0 | |
| 2025 (remaining six months) | \u00a0 | $ | 36,321 | \u00a0 |
| 2026 | \u00a0 | \u00a0 | 72,641 | \u00a0 |
| 2027 | \u00a0 | \u00a0 | 72,641 | \u00a0 |
| 2028 | \u00a0 | \u00a0 | 72,641 | \u00a0 |
| 2029 | \u00a0 | \u00a0 | 72,641 | \u00a0 |
| Thereafter | \u00a0 | \u00a0 | 361,373 | \u00a0 |
| Total | \u00a0 | $ | 688,258 | \u00a0 |
\u00a0
\n \n \n "}]},{"name":"rpt:f-877","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Customer relationships & distribution channels | \u00a0 | $ | 597,441 | \u00a0 | \u00a0 | $ | 603,939 | \u00a0 |
| Licenses, permits & applications | \u00a0 | \u00a0 | 364,612 | \u00a0 | \u00a0 | \u00a0 | 368,057 | \u00a0 |
| Non-compete agreements | \u00a0 | \u00a0 | 12,346 | \u00a0 | \u00a0 | \u00a0 | 12,403 | \u00a0 |
| Intellectual property, trademarks, knowhow & brands | \u00a0 | \u00a0 | 602,179 | \u00a0 | \u00a0 | \u00a0 | 608,672 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | 1,576,578 | \u00a0 | \u00a0 | $ | 1,593,071 | \u00a0 |
| Less: accumulated amortization | \u00a0 | \u00a0 | (294,089 | ) | \u00a0 | \u00a0 | (261,758 | ) |
| Less: impairments | \u00a0 | \u00a0 | (415,844 | ) | \u00a0 | \u00a0 | (415,844 | ) |
| Total | \u00a0 | $ | 866,645 | \u00a0 | \u00a0 | $ | 915,469 | \u00a0 |
| \u00a0 | \u00a0 | Amortization | \u00a0 | |
| 2025 (remaining six months) | \u00a0 | $ | 36,321 | \u00a0 |
| 2026 | \u00a0 | \u00a0 | 72,641 | \u00a0 |
| 2027 | \u00a0 | \u00a0 | 72,641 | \u00a0 |
| 2028 | \u00a0 | \u00a0 | 72,641 | \u00a0 |
| 2029 | \u00a0 | \u00a0 | 72,641 | \u00a0 |
| Thereafter | \u00a0 | \u00a0 | 361,373 | \u00a0 |
| Total | \u00a0 | $ | 688,258 | \u00a0 |
Note 6. Goodwill
\n\u00a0
\nThe following table shows the carrying amount of goodwill by reporting units:
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| Reporting Unit | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Cannabis | \u00a0 | $ | 2,640,669 | \u00a0 | \u00a0 | $ | 2,640,669 | \u00a0 |
| Distribution | \u00a0 | \u00a0 | 4,458 | \u00a0 | \u00a0 | \u00a0 | 4,458 | \u00a0 |
| Beverage | \u00a0 | \u00a0 | 120,802 | \u00a0 | \u00a0 | \u00a0 | 120,802 | \u00a0 |
| Wellness | \u00a0 | \u00a0 | 77,470 | \u00a0 | \u00a0 | \u00a0 | 77,470 | \u00a0 |
| Effect of foreign exchange | \u00a0 | \u00a0 | (373 | ) | \u00a0 | \u00a0 | 7,916 | \u00a0 |
| Impairments | \u00a0 | \u00a0 | (842,431 | ) | \u00a0 | \u00a0 | (842,431 | ) |
| Total | \u00a0 | $ | 2,000,595 | \u00a0 | \u00a0 | $ | 2,008,884 | \u00a0 |
\u00a0
\n \n \n "}]},{"name":"rpt:f-905","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfGoodwillTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| Reporting Unit | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Cannabis | \u00a0 | $ | 2,640,669 | \u00a0 | \u00a0 | $ | 2,640,669 | \u00a0 |
| Distribution | \u00a0 | \u00a0 | 4,458 | \u00a0 | \u00a0 | \u00a0 | 4,458 | \u00a0 |
| Beverage | \u00a0 | \u00a0 | 120,802 | \u00a0 | \u00a0 | \u00a0 | 120,802 | \u00a0 |
| Wellness | \u00a0 | \u00a0 | 77,470 | \u00a0 | \u00a0 | \u00a0 | 77,470 | \u00a0 |
| Effect of foreign exchange | \u00a0 | \u00a0 | (373 | ) | \u00a0 | \u00a0 | 7,916 | \u00a0 |
| Impairments | \u00a0 | \u00a0 | (842,431 | ) | \u00a0 | \u00a0 | (842,431 | ) |
| Total | \u00a0 | $ | 2,000,595 | \u00a0 | \u00a0 | $ | 2,008,884 | \u00a0 |
Note 7.\u00a0Business\u00a0acquisitions
\n\u00a0\u00a0
\nAcquisition of Craft\u00a0Beverage\u00a0Business Portfolio
\n\u00a0
\nOn\u00a0\u00a0 September 29, 2023,\u00a0Tilray acquired a portfolio of beverage brands, assets and businesses comprising\u00a0 craft beer and beverage brands from Anheuser-Busch Companies, LLC, (\"AB\") including breweries and brewpubs associated with them (the \u201cCraft\u00a0Acquisition\u201d). The acquired businesses/brands\u00a0include\u00a0Shock Top,\u00a0Breckenridge Brewery,\u00a0Blue Point Brewing Company,\u00a010\u00a0Barrel Brewing Company,\u00a0Redhook Brewery, Widmer Brothers Brewing,\u00a0Square Mile Cider Company, and HiBall Energy. The Company paid a total purchase price\u00a0of $83,658\u00a0in cash, net of a working capital adjustment at closing of $1,342.\u00a0
\n\u00a0
\nDuring the period ended November 30, 2024, the Company decreased the fair value of inventory by $500,\u00a0 increased the fair value of capital assets by $6,799, decreased the fair value of finance lease, right-of-use assets by $2,999 and\u00a0increased accounts payable and accrued liabilities by $3,300 and thus\u00a0completed the determination of the fair value of the net assets acquired. The table below summarizes the fair value of the assets acquired and liabilities assumed at the acquisition date:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash consideration | \u00a0 | $ | 83,658 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 77 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 20,993 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 573 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Capital assets | \u00a0 | \u00a0 | 82,913 | \u00a0 |
| Finance lease, right-of-use assets | \u00a0 | \u00a0 | 42,497 | \u00a0 |
| Operating lease, right-of-use assets | \u00a0 | \u00a0 | 7,677 | \u00a0 |
| Other assets | \u00a0 | \u00a0 | 108 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 154,838 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 18,006 | \u00a0 |
| Current portion of finance lease liabilities | \u00a0 | \u00a0 | 1,031 | \u00a0 |
| Current portion of operating lease liabilities | \u00a0 | \u00a0 | 1,408 | \u00a0 |
| Long - term liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities | \u00a0 | \u00a0 | 44,465 | \u00a0 |
| Operating lease liabilities | \u00a0 | \u00a0 | 6,270 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 71,180 | \u00a0 |
| Total net assets acquired | \u00a0 | \u00a0 | 83,658 | \u00a0 |
\u00a0
\nIn the event that the Craft\u00a0Acquisition had occurred on June 1, 2023, the Company would have had, on an unaudited proforma basis, additional net\u00a0revenue of approximately\u00a0$14,000 and $55,000 for the\u00a0three and six months ended November 30, 2023, respectively, and its consolidated net loss and comprehensive net loss would have increased by approximately\u00a0$2,000 and $5,000 for the\u00a0three and six months ended November 30, 2023, respectively. This unaudited pro forma financial information does\u00a0not\u00a0reflect the realization of any expected ongoing synergies relating to the integration of the Craft\u00a0Acquisition.
\n\u00a0
\nAcquisition of Craft\u00a0Beverage\u00a0Business Portfolio II
\n\u00a0
\nEffective September 1, 2024,\u00a0the Company acquired craft beer brands and breweries from Molson Coors Beverage Company\u00a0(\"Molson\") including Atwater Brewery,\u00a0Hop Valley Brewing Company,\u00a0Terrapin Beer Co., and\u00a0Revolver Brewing (the \u201cCraft\u00a0Acquisition II\u201d).\u00a0The purpose of the acquisition is to continue broadening Tilray's beverage brand strategy. In consideration for the acquisition, the Company paid a total purchase price\u00a0of $23,079\u00a0in cash, which is\u00a0subject to certain customary post-closing working capital adjustments.
\n\u00a0
\nThe Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value\u00a0 may\u00a0be subject to adjustments pending completion of final valuations and post-closing adjustments.\u00a0The table below summarizes the preliminary estimated fair value of the assets acquired and the liabilities assumed for the Craft Acquisition II\u00a0at the effective acquisition date\u00a0as follows:\u00a0
\n\u00a0
\n \n| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash consideration | \u00a0 | $ | 23,079 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 4,869 | \u00a0 |
| Accounts receivable | \u00a0 | \u00a0 | 1,993 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 7,344 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 185 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Capital assets | \u00a0 | \u00a0 | 17,366 | \u00a0 |
| Finance lease, right-of-use assets | \u00a0 | \u00a0 | 1,869 | \u00a0 |
| Operating lease, right-of-use assets | \u00a0 | \u00a0 | 1,884 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 35,510 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 8,678 | \u00a0 |
| Current portion of finance lease liabilities | \u00a0 | \u00a0 | 354 | \u00a0 |
| Current portion of operating lease liabilities | \u00a0 | \u00a0 | 564 | \u00a0 |
| Long - term liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities | \u00a0 | \u00a0 | 1,515 | \u00a0 |
| Operating lease liabilities | \u00a0 | \u00a0 | 1,320 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 12,431 | \u00a0 |
| Total net assets acquired | \u00a0 | \u00a0 | 23,079 | \u00a0 |
\u00a0
\nIn the event that the Craft Acquisition II had occurred on June 1, 2023, the Company would have had, on an unaudited proforma basis, additional net\u00a0revenue of approximately and $13,700 for the three and six months ended November 30, 2024 and\u00a0approximately $14,000\u00a0and $31,000 for the\u00a0three and six months ended November 30, 2023, respectively, and its consolidated net loss and comprehensive net loss would have increased by approximately\u00a0 and $4,000 for the three and six months ended November 30, 2024 and approximately $5,500 and $9,600 for the\u00a0three and six months ended November 30, 2023, respectively. This unaudited pro forma financial information does\u00a0not\u00a0reflect the realization of any expected ongoing synergies relating to the integration of the Craft Acquisition II.
\n\u00a0
\n "}]},{"name":"rpt:f-921","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireBusinessesGross","xbrl:period":"2023-09-29T00:00:00/2023-09-30T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:CraftBeverageBusinessAcquisitionMember"},"factValues":[{"value":"83658000","decimals":-3}]},{"name":"rpt:f-922","factDimensions":{"xbrl:concept":"tlry:WorkingCapitalAdjustment","xbrl:period":"2023-09-30T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:CraftBeverageBusinessAcquisitionMember"},"factValues":[{"value":"1342000","decimals":-3}]},{"name":"rpt:f-923","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentInventory","xbrl:period":"2024-09-30T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:CraftBeverageBusinessAcquisitionMember"},"factValues":[{"value":"-500000","decimals":-5}]},{"name":"rpt:f-924","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment","xbrl:period":"2024-09-30T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:CraftBeverageBusinessAcquisitionMember"},"factValues":[{"value":"6799000","decimals":-3}]},{"name":"rpt:f-925","factDimensions":{"xbrl:concept":"tlry:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssetsFinanceLeaseRightOfUseAssets","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:CraftBeverageBusinessAcquisitionMember"},"factValues":[{"value":"-2999000","decimals":-3}]},{"name":"rpt:f-926","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentFinancialLiabilities","xbrl:period":"2024-09-30T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:CraftBeverageBusinessAcquisitionMember"},"factValues":[{"value":"3300000","decimals":-5}]},{"name":"rpt:f-927","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash consideration | \u00a0 | $ | 83,658 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 77 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 20,993 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 573 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Capital assets | \u00a0 | \u00a0 | 82,913 | \u00a0 |
| Finance lease, right-of-use assets | \u00a0 | \u00a0 | 42,497 | \u00a0 |
| Operating lease, right-of-use assets | \u00a0 | \u00a0 | 7,677 | \u00a0 |
| Other assets | \u00a0 | \u00a0 | 108 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 154,838 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 18,006 | \u00a0 |
| Current portion of finance lease liabilities | \u00a0 | \u00a0 | 1,031 | \u00a0 |
| Current portion of operating lease liabilities | \u00a0 | \u00a0 | 1,408 | \u00a0 |
| Long - term liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities | \u00a0 | \u00a0 | 44,465 | \u00a0 |
| Operating lease liabilities | \u00a0 | \u00a0 | 6,270 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 71,180 | \u00a0 |
| Total net assets acquired | \u00a0 | \u00a0 | 83,658 | \u00a0 |
| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash consideration | \u00a0 | $ | 23,079 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 4,869 | \u00a0 |
| Accounts receivable | \u00a0 | \u00a0 | 1,993 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 7,344 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 185 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Capital assets | \u00a0 | \u00a0 | 17,366 | \u00a0 |
| Finance lease, right-of-use assets | \u00a0 | \u00a0 | 1,869 | \u00a0 |
| Operating lease, right-of-use assets | \u00a0 | \u00a0 | 1,884 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 35,510 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 8,678 | \u00a0 |
| Current portion of finance lease liabilities | \u00a0 | \u00a0 | 354 | \u00a0 |
| Current portion of operating lease liabilities | \u00a0 | \u00a0 | 564 | \u00a0 |
| Long - term liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities | \u00a0 | \u00a0 | 1,515 | \u00a0 |
| Operating lease liabilities | \u00a0 | \u00a0 | 1,320 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 12,431 | \u00a0 |
| Total net assets acquired | \u00a0 | \u00a0 | 23,079 | \u00a0 |
Note 8.\u00a0Convertible notes receivable
\n\u00a0
\nConvertible notes receivable is comprised of the following:
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| MedMen Convertible Note | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 |
| Deduct - current portion | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total convertible notes receivable, non current portion | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 32,000 | \u00a0 |
\u00a0
\n \n \nMedMen Convertible Note
\n\u00a0
\nOn August 31, 2021, the Company issued\u00a09,817,061 shares valued at $117,804 to acquire\u00a068% interest in Superhero Acquisition L.P. (\u201cSH Acquisition\u201d), which purchased a senior secured convertible note issued by MedMen (the \"MedMen Convertible Note\"), together with certain associated warrants to acquire Class B subordinate voting shares of MedMen, in the principal amount of $165,799. The MedMen Convertible Note bears interest at the Secured Overnight Financing Rate (\"SOFR\") plus\u00a06%, with a SOFR floor of\u00a02.5% with any accrued interest being added to the outstanding principal amount. The outstanding principal amount, together with accrued interest\u00a0is to be paid on August 17, 2028, the\u00a0maturity date of the MedMen Convertible Note. SH Acquisition was also granted \u201ctop-up\u201d rights enabling it (and its limited partners) to maintain its percentage ownership (on an \u201cas-converted\u201d basis) in the event that MedMen issues equity securities.\u00a0SH Acquisition\u2019s ability to convert the MedMen Convertible Note\u00a0and exercise the Warrants is dependent upon U.S. federal legalization of cannabis or Tilray\u2019s waiver of such requirement as well as any additional regulatory approvals.\u00a0
\n\u00a0
\nDuring the\u00a0three and six months ended November 30, 2024\u00a0there were\u00a0no additional changes in fair value and the note remained valued at $32,000 as of November 30, 2024 compared to $32,000 as of May 31, 2024.
\n\u00a0
\nThe Company\u00a0did not derive any revenue or cash from MedMen's operations, and fully complies with all limitations imposed by applicable U.S. law and regulations in connection with its ownership of the MedMen Convertible Note.\u00a0In addition, since the fiscal year ended May 31, 2024, the Company has\u00a0 recognized any\u00a0interest income on the MedMen Convertible Note, nor did the Company recognize any interest income for the three and six months ended November 30, 2024, which would have\u00a0increased\u00a0its value.\u00a0
\n "}]},{"name":"rpt:f-972","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| MedMen Convertible Note | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 |
| Deduct - current portion | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total convertible notes receivable, non current portion | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 32,000 | \u00a0 |
Note 9. Long term investments
\n\u00a0
\nLong term investments consisted of the following:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \nNovember 30, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n||
| Equity investments measured at fair value | \n \u00a0 | \n$ | \n1,916 | \n\u00a0 | \n\u00a0 | \n$ | \n2,359 | \n\u00a0 | \n
| Equity investments under measurement alternative | \n \u00a0 | \n\u00a0 | \n5,500 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n5,500 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n7,416 | \n\u00a0 | \n\u00a0 | \n$ | \n7,859 | \n\u00a0 | \n
\u00a0 \u00a0 \u00a0
\n \n \n "}]},{"name":"rpt:f-989","factDimensions":{"xbrl:concept":"us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \nNovember 30, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n||
| Equity investments measured at fair value | \n \u00a0 | \n$ | \n1,916 | \n\u00a0 | \n\u00a0 | \n$ | \n2,359 | \n\u00a0 | \n
| Equity investments under measurement alternative | \n \u00a0 | \n\u00a0 | \n5,500 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n5,500 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n7,416 | \n\u00a0 | \n\u00a0 | \n$ | \n7,859 | \n\u00a0 | \n
Note 10. Bank indebtedness
\n\u00a0
\nAphria Inc., a subsidiary of the Company,\u00a0has an operating line of credit in the amount of which bears interest at the lender\u2019s prime rate plus 75 basis points. As of November 30, 2024, the Company has drawn on the line of credit. The operating line of credit is secured by a security interest on certain real property located\u00a0at 265 Talbot St. West, Leamington, Ontario.
\n\u00a0
\nCC Pharma GmbH, a subsidiary of the Company, has \u00a0operating lines of credit in the amounts of\u00a0\u00a0and\u00a0\u00a0These lines\u00a0bear interest at\u00a0Euro Short-Term Rate (\"ESTR\") plus 2.50% and Euro Interbank Offered Rate (\"EURIBOR\") plus 4.00%, respectively. As of November 30, 2024, a total of ($7,751) was drawn down from the total available credit of\u00a0\u00a0The operating line\u00a0of credit for \u00a0is secured by an interest in the inventory of CC Pharma GmbH as well as\u00a0the Densborn, Germany production facility and underlying real property. The operating line of credit for is unsecured.
\n\u00a0
\nAmerican Beverage Crafts Group Inc. (\"ABC Group\"),\u00a0a subsidiary of the Company, has a revolving credit facility of $30,000, which bears interest at SOFR plus an applicable margin. As of November 30, 2024, the Company has drawn down $10,000\u00a0on the revolving line of credit. The revolving credit facility is secured by ABC Group's assets and includes a corporate guarantee by a subsidiary of the Company.\u00a0
\n\u00a0
\n "}]},{"name":"rpt:f-997","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentBasisSpreadOnVariableRate1","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember","us-gaap:VariableRateAxis":"us-gaap:PrimeRateMember"},"factValues":[{"value":"0.75","decimals":2}]},{"name":"rpt:f-998","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentBasisSpreadOnVariableRate1","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","srt:ConsolidatedEntitiesAxis":"tlry:CCPharmaGmbHMember","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember","us-gaap:VariableRateAxis":"tlry:EuroShorttermRateMember"},"factValues":[{"value":"0.025","decimals":3}]},{"name":"rpt:f-999","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentBasisSpreadOnVariableRate1","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","srt:ConsolidatedEntitiesAxis":"tlry:CCPharmaGmbHMember","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember","us-gaap:VariableRateAxis":"tlry:EuroInterbankOfferedRateMember"},"factValues":[{"value":"0.04","decimals":2}]},{"name":"rpt:f-1000","factDimensions":{"xbrl:concept":"us-gaap:LineOfCredit","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","srt:ConsolidatedEntitiesAxis":"tlry:CCPharmaGmbHMember","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember"},"factValues":[{"value":"7751000","decimals":-3}]},{"name":"rpt:f-1001","factDimensions":{"xbrl:concept":"us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","srt:ConsolidatedEntitiesAxis":"tlry:AmericanBeverageCraftsGroupIncMember","us-gaap:CreditFacilityAxis":"us-gaap:RevolvingCreditFacilityMember"},"factValues":[{"value":"30000000","decimals":-7}]},{"name":"rpt:f-1002","factDimensions":{"xbrl:concept":"us-gaap:LineOfCredit","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","srt:ConsolidatedEntitiesAxis":"tlry:AmericanBeverageCraftsGroupIncMember","us-gaap:CreditFacilityAxis":"us-gaap:RevolvingCreditFacilityMember"},"factValues":[{"value":"10000000","decimals":-7}]},{"name":"rpt:f-1003","factDimensions":{"xbrl:concept":"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 11. Accounts payable and accrued liabilities
\n\u00a0
\nAccounts payable and accrued liabilities are comprised of:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \nNovember 30, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n||
| Trade payables | \n \u00a0 | \n$ | \n99,077 | \n\u00a0 | \n\u00a0 | \n$ | \n105,392 | \n\u00a0 | \n
| Accrued liabilities | \n \u00a0 | \n\u00a0 | \n87,871 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n92,424 | \n\u00a0 | \n
| Litigation accrual | \n \u00a0 | \n\u00a0 | \n19,610 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n24,378 | \n\u00a0 | \n
| Accrued payroll and employment related taxes | \n \u00a0 | \n\u00a0 | \n4,523 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n6,154 | \n\u00a0 | \n
| Income taxes payable | \n \u00a0 | \n\u00a0 | \n1,380 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,092 | \n\u00a0 | \n
| Accrued interest | \n \u00a0 | \n\u00a0 | \n5,161 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,217 | \n\u00a0 | \n
| Sales taxes payable | \n \u00a0 | \n\u00a0 | \n4,046 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n5,300 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n221,668 | \n\u00a0 | \n\u00a0 | \n$ | \n241,957 | \n\u00a0 | \n
\u00a0 \u00a0 \u00a0
\n \n \n "}]},{"name":"rpt:f-1004","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \nNovember 30, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n||
| Trade payables | \n \u00a0 | \n$ | \n99,077 | \n\u00a0 | \n\u00a0 | \n$ | \n105,392 | \n\u00a0 | \n
| Accrued liabilities | \n \u00a0 | \n\u00a0 | \n87,871 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n92,424 | \n\u00a0 | \n
| Litigation accrual | \n \u00a0 | \n\u00a0 | \n19,610 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n24,378 | \n\u00a0 | \n
| Accrued payroll and employment related taxes | \n \u00a0 | \n\u00a0 | \n4,523 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n6,154 | \n\u00a0 | \n
| Income taxes payable | \n \u00a0 | \n\u00a0 | \n1,380 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,092 | \n\u00a0 | \n
| Accrued interest | \n \u00a0 | \n\u00a0 | \n5,161 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,217 | \n\u00a0 | \n
| Sales taxes payable | \n \u00a0 | \n\u00a0 | \n4,046 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n5,300 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n221,668 | \n\u00a0 | \n\u00a0 | \n$ | \n241,957 | \n\u00a0 | \n
Note 12. Long-term debt
\n\u00a0
\nThe following table sets forth the net carrying amount of long-term debt instruments:
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Credit facility - C$ - Canadian prime interest rate plus an applicable margin, -year term, with a -year amortization, repayable in blended monthly payments, due in | \u00a0 | $ | 35,500 | \u00a0 | \u00a0 | $ | 39,420 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 9,533 | \u00a0 | \u00a0 | \u00a0 | 10,212 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 11,700 | \u00a0 | \u00a0 | \u00a0 | 12,422 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 213 | \u00a0 | \u00a0 | \u00a0 | 263 | \u00a0 |
| Mortgage payable - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 2,018 | \u00a0 | \u00a0 | \u00a0 | 2,089 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in quarterly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 205 | \u00a0 | \u00a0 | \u00a0 | 417 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in monthly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 2,745 | \u00a0 | \u00a0 | \u00a0 | 3,151 | \u00a0 |
| Mortgage payable - $ - EURIBOR rate plus %, -year term, repayable in monthly installments of $ to $, due in | \u00a0 | \u00a0 | 19,787 | \u00a0 | \u00a0 | \u00a0 | 20,066 | \u00a0 |
| Term loan - $ - SOFR plus an applicable margin, -year term, repayable in quarterly installments of $ to $ due in | \u00a0 | \u00a0 | 83,813 | \u00a0 | \u00a0 | \u00a0 | 86,626 | \u00a0 |
| Carrying amount of long-term debt | \u00a0 | \u00a0 | 165,514 | \u00a0 | \u00a0 | \u00a0 | 174,666 | \u00a0 |
| Unamortized financing fees | \u00a0 | \u00a0 | (805 | ) | \u00a0 | \u00a0 | (808 | ) |
| Net carrying amount | \u00a0 | \u00a0 | 164,709 | \u00a0 | \u00a0 | \u00a0 | 173,858 | \u00a0 |
| Less principal portion included in current liabilities | \u00a0 | \u00a0 | (15,838 | ) | \u00a0 | \u00a0 | (15,506 | ) |
| Total non-current portion of long-term debt | \u00a0 | $ | 148,871 | \u00a0 | \u00a0 | $ | 158,352 | \u00a0 |
\u00a0
\n \n \n "}]},{"name":"rpt:f-1022","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfDebtInstrumentsTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Credit facility - C$ - Canadian prime interest rate plus an applicable margin, -year term, with a -year amortization, repayable in blended monthly payments, due in | \u00a0 | $ | 35,500 | \u00a0 | \u00a0 | $ | 39,420 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 9,533 | \u00a0 | \u00a0 | \u00a0 | 10,212 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 11,700 | \u00a0 | \u00a0 | \u00a0 | 12,422 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 213 | \u00a0 | \u00a0 | \u00a0 | 263 | \u00a0 |
| Mortgage payable - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 2,018 | \u00a0 | \u00a0 | \u00a0 | 2,089 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in quarterly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 205 | \u00a0 | \u00a0 | \u00a0 | 417 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in monthly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 2,745 | \u00a0 | \u00a0 | \u00a0 | 3,151 | \u00a0 |
| Mortgage payable - $ - EURIBOR rate plus %, -year term, repayable in monthly installments of $ to $, due in | \u00a0 | \u00a0 | 19,787 | \u00a0 | \u00a0 | \u00a0 | 20,066 | \u00a0 |
| Term loan - $ - SOFR plus an applicable margin, -year term, repayable in quarterly installments of $ to $ due in | \u00a0 | \u00a0 | 83,813 | \u00a0 | \u00a0 | \u00a0 | 86,626 | \u00a0 |
| Carrying amount of long-term debt | \u00a0 | \u00a0 | 165,514 | \u00a0 | \u00a0 | \u00a0 | 174,666 | \u00a0 |
| Unamortized financing fees | \u00a0 | \u00a0 | (805 | ) | \u00a0 | \u00a0 | (808 | ) |
| Net carrying amount | \u00a0 | \u00a0 | 164,709 | \u00a0 | \u00a0 | \u00a0 | 173,858 | \u00a0 |
| Less principal portion included in current liabilities | \u00a0 | \u00a0 | (15,838 | ) | \u00a0 | \u00a0 | (15,506 | ) |
| Total non-current portion of long-term debt | \u00a0 | $ | 148,871 | \u00a0 | \u00a0 | $ | 158,352 | \u00a0 |
Note 13. Convertible debentures payable
\n\u00a0
\nThe following table sets forth the net carrying amount of the convertible debentures payable:
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| % Convertible Notes (\"TLRY 27\") | \u00a0 | $ | 122,735 | \u00a0 | \u00a0 | $ | 129,583 | \u00a0 |
| % Convertible Notes (\"APHA 24\") | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 330 | \u00a0 |
| Total | \u00a0 | \u00a0 | 122,735 | \u00a0 | \u00a0 | \u00a0 | 129,913 | \u00a0 |
| Deduct - current portion | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 330 | \u00a0 |
| Total convertible debentures payable, non current portion | \u00a0 | $ | 122,735 | \u00a0 | \u00a0 | $ | 129,583 | \u00a0 |
\u00a0
\nTLRY 27 Notes
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | 172,500 | \u00a0 | \u00a0 | $ | 172,500 | \u00a0 |
| Debt settlement | \u00a0 | \u00a0 | (16,500 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Unamortized discount | \u00a0 | \u00a0 | (33,265 | ) | \u00a0 | \u00a0 | (42,917 | ) |
| Net carrying amount | \u00a0 | $ | 122,735 | \u00a0 | \u00a0 | $ | 129,583 | \u00a0 |
\u00a0
\nThe TLRY\u00a027\u00a0convertible debentures\u00a0were issued\u00a0on\u00a0 May 30, 2023 and on June 9, 2023 by way of overallotment,\u00a0in the principal amount of $172,500 (the \u201cTLRY 27 Notes\u201d). The TLRY 27 Notes\u00a0bear interest at a rate of\u00a05.20% per annum, payable semi-annually in arrears on\u00a0 June 15\u00a0and\u00a0 December 15\u00a0of each year, and mature on\u00a0 June 15, 2027,\u00a0unless earlier converted. The TLRY 27 Notes are Tilray\u2019s general unsecured obligations and rank senior in right of payment to all of Tilray\u2019s indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment with any of Tilray\u2019s unsecured indebtedness that is not so subordinated, including TLRY 23 and APHA 24, effectively junior in right of payment to any of Tilray\u2019s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of Tilray\u2019s current or future subsidiaries.\u00a0Noteholders will have the right to convert their TLRY\u00a027\u00a0Notes into shares of Tilray\u2019s Common Stock at their option, at any time, until the close of business on the\u00a0second\u00a0scheduled trading day immediately before\u00a0 June 15, 2027.\u00a0The initial conversion rate is\u00a0376.6478\u00a0shares per\u00a0$1,000\u00a0principal amount of TLRY\u00a027\u00a0Notes, which represents a conversion price of approximately\u00a0$2.66\u00a0per share. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.
\n\u00a0
\nThe TLRY\u00a027\u00a0Notes will be redeemable, in whole and\u00a0not\u00a0in part, at Tilray\u2019s option at any time on or after\u00a0\u00a0 June 20, 2025\u00a0at a cash redemption price equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price of Tilray\u2019s Common Stock exceeds\u00a0130% of the conversion price for a specified period of time. If certain corporate events that constitute a fundamental change occur, then, subject to a limited exception, noteholders\u00a0 may\u00a0require\u00a0Tilray\u00a0to repurchase their TLRY\u00a027\u00a0Notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. In connection with the Company\u2019s offering of the TLRY\u00a027\u00a0Notes, the Company entered into a share lending agreement with an affiliate of\u00a0Jefferies LLC\u00a0(the \u201cShare Borrower\u201d), pursuant to which it lent\u00a0to the Share Borrower\u00a038,500,000\u00a0shares of the Company\u2019s Common Stock (the \"Borrowed Shares\"). The Borrowed Shares were newly-issued shares,\u00a0will be held as treasury shares until the expiration or early termination of the share lending agreement\u00a0and may be used by purchasers of the TLRY\u00a027\u00a0Notes\u00a0to sell up to\u00a038,500,000\u00a0shares of the Company\u2019s Common Stock. The fair value of the share lending agreement has been recorded as part of the unamortized discount on the debenture. The Company expects that the selling stockholders will use their position created by such sales to establish their initial hedge with respect to their investments in the TLRY\u00a027\u00a0Notes. The Company did\u00a0not\u00a0receive any proceeds from the sale of the Borrowed Shares.\u00a0
\n\u00a0
\nOn\u00a0 September 12, 2024 and November 4, 2024,\u00a0the Company exchanged $7,500 and $9,000\u00a0of its TLRY\u00a027\u00a0Notes for cancellation, respectively, by issuing 10,034,635 Common Stock and paying $290 of cash to settle both principal and accrued interest. Upon exchanging\u00a0the TLRY\u00a027\u00a0Notes, a portion of the\u00a0settlement consideration was allocated to the equity component of the instrument and\u00a0was\u00a0recognized as a $4,931\u00a0reduction of additional paid-in capital in the Consolidated Statements of Changes in Equity. Additionally, this repurchase resulted in a gain\u00a0of $679 which was recorded in other non-operating (losses) gains, net as shown in Note\u00a024\u00a0(Non-operating income (expense)).\u00a0Following consummation of the exchange, the number of outstanding Borrowed Shares of Common Stock was reduced by 3,682,609 shares which were then returned\u00a0as Treasury Stock.\u00a0As of\u00a0 November\u00a030, 2024\u00a0and May 31, 2024, a total of 34,817,391\u00a0and\u00a038,500,000\u00a0shares remained outstanding under the\u00a0share lending\u00a0arrangement, respectively.\u00a0
\n\u00a0
\nDuring the three and six months ended November 30, 2024, the Company recognized interest expense\u00a0of $2,133 and $4,375 and accretion of amortized discount interest of $2,919 and\u00a0$5,985\u00a0respectively. During the three and six months ended November 30,\u00a02023, the Company recognized interest expense of $2,423\u00a0and $4,485\u00a0and accretion of amortized discount interest of $2,829\u00a0and\u00a0$5,624.\u00a0
\n\u00a0
\nAs at\u00a0 November 30, 2024, there was $156,000\u00a0principal outstanding compared to $172,500 principal outstanding as at May 31,\u00a02024.
\n\u00a0
\nAPHA 24 Notes
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 350,000 | \u00a0 |
| Debt settlement | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (349,670 | ) |
| Fair value adjustment | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Net carrying amount | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 330 | \u00a0 |
\u00a0
\nThe APHA 24 convertible debentures, were entered into in April 2019, in the principal amount of $350,000, bore interest at a rate of 5.25% per annum, and were payable semi-annually in arrears on June 1 and December 1 of each year, and matured on June 1, 2024\u00a0(the \"APHA 24 Notes\").\u00a0On June 1, 2024,\u00a0the Company repaid the remaining principal\u00a0of the APHA 24\u00a0Notes in cash upon maturity.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1052","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebtTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| % Convertible Notes (\"TLRY 27\") | \u00a0 | $ | 122,735 | \u00a0 | \u00a0 | $ | 129,583 | \u00a0 |
| % Convertible Notes (\"APHA 24\") | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 330 | \u00a0 |
| Total | \u00a0 | \u00a0 | 122,735 | \u00a0 | \u00a0 | \u00a0 | 129,913 | \u00a0 |
| Deduct - current portion | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 330 | \u00a0 |
| Total convertible debentures payable, non current portion | \u00a0 | $ | 122,735 | \u00a0 | \u00a0 | $ | 129,583 | \u00a0 |
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | 172,500 | \u00a0 | \u00a0 | $ | 172,500 | \u00a0 |
| Debt settlement | \u00a0 | \u00a0 | (16,500 | ) | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Unamortized discount | \u00a0 | \u00a0 | (33,265 | ) | \u00a0 | \u00a0 | (42,917 | ) |
| Net carrying amount | \u00a0 | $ | 122,735 | \u00a0 | \u00a0 | $ | 129,583 | \u00a0 |
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 350,000 | \u00a0 |
| Debt settlement | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (349,670 | ) |
| Fair value adjustment | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Net carrying amount | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 330 | \u00a0 |
Note 14. Warrant liability
\n\u00a0
\nAs of November 30, 2024 and May 31, 2024, there were 6,209,000 warrants outstanding, with an original exercise price of $5.95 per warrant, expiring September 17, 2025. Each warrant is exercisable for Common Stock of the Company.
\n\u00a0
\nThe warrants contain anti-dilution price protection features, which adjust the exercise price of the warrants if the Company subsequently issues Common Stock at a price lower than the exercise price of the warrants. In the event additional warrants or convertible debt are issued with a lower and/or variable exercise price, the exercise price of the warrants will be adjusted accordingly. During the six\u00a0months ended November 30, 2024, the Company issued shares of its Common Stock which triggered the anti-dilution price protection feature and, accordingly, lowered\u00a0the exercise price of each warrant to $1.29. These warrants are classified as liabilities as they are to be settled in registered shares, and the registration statement is required to be active, unless such shares may be subject to an applicable exemption from registration requirements. The holders, at their sole discretion, may elect to affect a cashless exercise, and be issued exempt securities in accordance with Section 3(a)(9) of the 1933 Act. In the event the Company does not maintain an effective registration statement, the Company may be required to pay a daily cash penalty equal to 1% of the number of shares of Common Stock due to be issued multiplied by any trading price of the Common Stock between the exercise date and the share delivery date, as selected by the holder. Alternatively, the Company may deliver registered Common Stock purchased by the Company in the open market. The Company may also be required to pay cash if it does not have sufficient authorized shares to deliver to the holders upon exercise.
\n\u00a0
\nUsing the Black Scholes pricing model (Level 3), the Company has estimated the fair value of the warrants outstanding as of\u00a0 November 30, 2024\u00a0to be\u00a0$0.273 per warrant.\u00a0In applying the Black Scholes pricing model (Level 3), the Company utilized the following assumptions: a risk-free interest rate of 3.23%, an expected volatility of 50%, an expected term of 0.80 years, strike price of $1.29\u00a0and fair value of Common Stock of $1.34.
\n\u00a0
\nThe expected volatility assumption utilized in the Black Scholes pricing model (Level 3) was calculated\u00a0using\u00a0both the historical and implied volatility of the Company\u2019s Common Stock.
\n "}]},{"name":"rpt:f-1105","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightOutstanding","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"6209000"}]},{"name":"rpt:f-1106","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD/xbrla:shares"},"factValues":[{"value":"5.95"}]},{"name":"rpt:f-1107","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"1.29"}]},{"name":"rpt:f-1108","factDimensions":{"xbrl:concept":"tlry:PercentageOfDailyCashPenalty","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"0.01","decimals":2}]},{"name":"rpt:f-1109","factDimensions":{"xbrl:concept":"tlry:EstimatedFairValueOfWarrantLiabilityPerWarrant","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member"},"factValues":[{"value":"0.273"}]},{"name":"rpt:f-1110","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputRiskFreeInterestRateMember"},"factValues":[{"value":"0.0323","decimals":4}]},{"name":"rpt:f-1111","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputPriceVolatilityMember"},"factValues":[{"value":"0.50","decimals":1}]},{"name":"rpt:f-1112","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputExpectedTermMember"},"factValues":[{"value":"0.8"}]},{"name":"rpt:f-1113","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputConversionPriceMember"},"factValues":[{"value":"1.29"}]},{"name":"rpt:f-1114","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputSharePriceMember"},"factValues":[{"value":"1.34"}]},{"name":"rpt:f-1115","factDimensions":{"xbrl:concept":"us-gaap:StockholdersEquityNoteDisclosureTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 15. Stockholders' equity\u00a0
\n\u00a0
\nIssued and outstanding
\n\u00a0
\nPursuant to its Fourth Amended and Restated Certificate of Incorporation, the total number of shares that the Company is authorized to issue is 1,208,000,000 shares, of which 1,198,000,000 shares shall be Common Stock (the \u201cCommon Stock\u201d), and 10,000,000\u00a0shares of which shall be Preferred Stock (the \u201cPreferred Stock\u201d). As of\u00a0 November 30, 2024, the Company had issued and outstanding\u00a0929,257,945\u00a0shares of Common Stock, 3,682,609 shares of Treasury Stock\u00a0(the \u201cTreasury\u00a0Stock\u201d)\u00a0and no\u00a0Preferred Stock. Historically, the Company has issued shares of its Common Stock in\u00a0consideration for acquisitions and other\u00a0strategic transactions, settlement of convertible notes,\u00a0settlement of litigation claims, in connection with public offerings and as payment of dividends to non-controlling interests for profit distributions.
\n\u00a0
\nDuring the six months ended November 30, 2024, the Company issued the following shares of Common Stock:
\n\u00a0
\n| \u00a0 | a) | 67,210,864 shares of Common Stock pursuant to\u00a0its At-the-Market (\u201cATM\u201d) program, which generated gross proceeds\u00a0of $114,342 and net proceeds of $111,516, after deducting\u00a0$2,826\u00a0in commissions and other fees associated with these issuances. |
| \u00a0 | b) | 10,034,635\u00a0shares of Common Stock to exchange\u00a0the\u00a0aggregate\u00a0principal of $16,500 of its TLRY 27\u00a0Notes for cancellation.\u00a0Upon exchanging\u00a0the TLRY\u00a027\u00a0Notes, a portion of the\u00a0settlement consideration was allocated to the equity component of the instrument and\u00a0was\u00a0recognized as a $4,931\u00a0reduction of additional paid-in capital. Following consummation of the exchange, the number of outstanding Borrowed Shares of Common Stock was reduced by approximately 3,682,609 shares which were then returned\u00a0as Treasury Stock, see Note 13\u00a0(Convertible debentures payable). |
| \u00a0 | c) | 13,217,588\u00a0shares of Common Stock to settle dividends payable to the non-controlling shareholders of Aphria Diamond in the amount of $23,824. |
| \u00a0 | d) | \u00a06,869,485\u00a0shares of Common Stock in connection with the exercise of previously awarded stock-based compensation awards. |
\u00a0
\nDuring the six months ended November 30, 2024, the Company granted 13,346,266 time-based Restricted Stock Units (\"RSUs\"),\u00a0and no performance-based RSUs. During the\u00a0six months ended November 30,\u00a02023, the Company granted 11,588,537 time-based RSUs and 7,566,146 performance-based RSUs. In connection with the 7,566,146 performance-based RSUs that were issued, the performance conditions associated with such awards will not be determined and adopted until a future date\u00a0and, therefore, the grant date has not been met for accounting purposes and no amounts have been recorded within the Consolidated Statement of Loss.\u00a0The Company's total stock-based compensation expense from RSUs incurred for\u00a0the three and\u00a0six months ended November 30, 2024\u00a0was $7,237 and $14,154, respectively,\u00a0compared to $8,201 and $16,458 for the three and six months ended\u00a0 November 30,\u00a02023, respectively.\u00a0
\n\u00a0
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1116","factDimensions":{"xbrl:concept":"tlry:SharesAuthorizedTotal","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"1208000000"}]},{"name":"rpt:f-1117","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesAuthorized","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"1198000000"}]},{"name":"rpt:f-1118","factDimensions":{"xbrl:concept":"us-gaap:PreferredStockSharesAuthorized","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"10000000"}]},{"name":"rpt:f-1119","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesIssued","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"929257945"}]},{"name":"rpt:f-1120","factDimensions":{"xbrl:concept":"us-gaap:TreasuryStockCommonShares","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"3682609"}]},{"name":"rpt:f-1121","factDimensions":{"xbrl:concept":"us-gaap:PreferredStockSharesIssued","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"0","decimals":-3}]},{"name":"rpt:f-1122","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesNewIssues","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"67210864"}]},{"name":"rpt:f-1123","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromIssuanceOfCommonStock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"114342000","decimals":-3}]},{"name":"rpt:f-1124","factDimensions":{"xbrl:concept":"tlry:NetProceedsFromIssuanceOfCommonStock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"111516000","decimals":-3}]},{"name":"rpt:f-1125","factDimensions":{"xbrl:concept":"us-gaap:PaymentsOfStockIssuanceCosts","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"2826000","decimals":-3}]},{"name":"rpt:f-1126","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesForTheRepaymentOfConvertibleDebt","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"tlry:TLRY27Member"},"factValues":[{"value":"10034635"}]},{"name":"rpt:f-1127","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentRepurchaseAmount","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"tlry:TLRY27Member"},"factValues":[{"value":"16500000","decimals":-5}]},{"name":"rpt:f-1128","factDimensions":{"xbrl:concept":"us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:DebtConversionByUniqueDescriptionAxis":"tlry:SettlementOfTlry27ConvertibleNoteWithShareIssuanceMember"},"factValues":[{"value":"4931000","decimals":-3}]},{"name":"rpt:f-1129","factDimensions":{"xbrl:concept":"us-gaap:DebtConversionConvertedInstrumentSharesIssued1","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:DebtConversionByUniqueDescriptionAxis":"tlry:SettlementOfTlry27ConvertibleNoteWithShareIssuanceMember","us-gaap:StatementEquityComponentsAxis":"us-gaap:TreasuryStockCommonMember"},"factValues":[{"value":"3682609"}]},{"name":"rpt:f-1130","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesSettlementOfFinancingLiability","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","srt:LitigationCaseAxis":"tlry:TilrayBrandsIncMedipharmHexoLitigationSettlementMember"},"factValues":[{"value":"13217588"}]},{"name":"rpt:f-1131","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodValueSettlementOfFinancingLiability","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","srt:LitigationCaseAxis":"tlry:TilrayBrandsIncMedipharmHexoLitigationSettlementMember"},"factValues":[{"value":"23824000","decimals":-3}]},{"name":"rpt:f-1132","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"6869485"}]},{"name":"rpt:f-1133","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:TimebasedRestrictedStockUnitsMember"},"factValues":[{"value":"13346266"}]},{"name":"rpt:f-1134","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:PerformancebasedRestrictedStockUnitsMember"},"factValues":[{"value":"0","decimals":-3}]},{"name":"rpt:f-1135","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:TimebasedRestrictedStockUnitsMember"},"factValues":[{"value":"11588537"}]},{"name":"rpt:f-1136","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:PerformancebasedRestrictedStockUnitsMember"},"factValues":[{"value":"7566146"}]},{"name":"rpt:f-1137","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:PerformancebasedRestrictedStockUnitsMember"},"factValues":[{"value":"7566146"}]},{"name":"rpt:f-1138","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2024-09-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"7237000","decimals":-3}]},{"name":"rpt:f-1139","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"14154000","decimals":-3}]},{"name":"rpt:f-1140","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"8201000","decimals":-3}]},{"name":"rpt:f-1141","factDimensions":{"xbrl:concept":"us-gaap:AllocatedShareBasedCompensationExpense","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"16458000","decimals":-3}]},{"name":"rpt:f-1142","factDimensions":{"xbrl:concept":"us-gaap:ComprehensiveIncomeNoteTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 16. Accumulated other comprehensive income (loss)
\n\u00a0
\nAccumulated other comprehensive income (loss) is comprised of foreign currency translation gain (loss) as follows:
\n\u00a0
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \n Total | \n \u00a0 | \n|
| Balance May 31, 2023 | \n \u00a0 | \n$ | \n(46,610 | \n) | \n
| Other comprehensive income (loss) | \n \u00a0 | \n\u00a0 | \n3,049 | \n\u00a0 | \n
| Balance August 31, 2023 | \n \u00a0 | \n$ | \n(43,561 | \n) | \n
| Other comprehensive income (loss) | \n \u00a0 | \n\u00a0 | \n5,194 | \n\u00a0 | \n
| Balance November 30, 2023 | \n \u00a0 | \n$ | \n(38,367 | \n) | \n
| \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n
| Balance May 31, 2024 | \n \u00a0 | \n$ | \n(43,499 | \n) | \n
| Other comprehensive income (loss) | \n \u00a0 | \n\u00a0 | \n3,622 | \n\u00a0 | \n
| Balance August 31, 2024 | \n \u00a0 | \n$ | \n(39,877 | \n) | \n
| Other comprehensive income (loss) | \n \u00a0 | \n\u00a0 | \n(8,080 | \n) | \n
| Balance November 30, 2024 | \n \u00a0 | \n$ | \n(47,957 | \n) | \n
\u00a0
\n "}]},{"name":"rpt:f-1143","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \n Total | \n \u00a0 | \n|
| Balance May 31, 2023 | \n \u00a0 | \n$ | \n(46,610 | \n) | \n
| Other comprehensive income (loss) | \n \u00a0 | \n\u00a0 | \n3,049 | \n\u00a0 | \n
| Balance August 31, 2023 | \n \u00a0 | \n$ | \n(43,561 | \n) | \n
| Other comprehensive income (loss) | \n \u00a0 | \n\u00a0 | \n5,194 | \n\u00a0 | \n
| Balance November 30, 2023 | \n \u00a0 | \n$ | \n(38,367 | \n) | \n
| \u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n
| Balance May 31, 2024 | \n \u00a0 | \n$ | \n(43,499 | \n) | \n
| Other comprehensive income (loss) | \n \u00a0 | \n\u00a0 | \n3,622 | \n\u00a0 | \n
| Balance August 31, 2024 | \n \u00a0 | \n$ | \n(39,877 | \n) | \n
| Other comprehensive income (loss) | \n \u00a0 | \n\u00a0 | \n(8,080 | \n) | \n
| Balance November 30, 2024 | \n \u00a0 | \n$ | \n(47,957 | \n) | \n
Note 17. Non-controlling interests
\n\u00a0
\nThe following are majority-owned subsidiaries of the Company and the percentage of ownership interest maintained by the Company is set forth in the parenthetical: \u00a0SH Acquisition (68%), CC Pharma Nordic ApS (75%), Aphria Diamond (51%), and Colcanna S.A.S. (90%).\u00a0
\n\u00a0
\nThe following table provides a summary of certain balance sheet information\u00a0before intercompany eliminations\u00a0relating to the above referenced majority-owned subsidiaries of the Company\u00a0in which there is a non-controlling interest as of November 30, 2024:
\n\u00a0
\n \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | November 30, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2024 | \u00a0 | |||||
| Current assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 14 | \u00a0 | \u00a0 | $ | 57,936 | \u00a0 | \u00a0 | $ | 49 | \u00a0 | \u00a0 | $ | 57,999 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | 116,314 | \u00a0 | \u00a0 | \u00a0 | 3,213 | \u00a0 | \u00a0 | \u00a0 | 151,527 | \u00a0 | |
| Current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (17 | ) | \u00a0 | \u00a0 | (123,533 | ) | \u00a0 | \u00a0 | (6,894 | ) | \u00a0 | \u00a0 | (130,444 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | (25,095 | ) | \u00a0 | \u00a0 | (1,452 | ) | \u00a0 | \u00a0 | (26,547 | ) | |
| Net assets | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | (3 | ) | \u00a0 | $ | 25,622 | \u00a0 | \u00a0 | $ | (5,084 | ) | \u00a0 | $ | 52,535 | \u00a0 |
\u00a0
\nThe following table provides a summary of certain balance sheet information\u00a0before intercompany eliminations\u00a0relating to the above referenced majority-owned subsidiaries of the Company\u00a0in which there is a non-controlling interest as of May 31, 2024:
\n\u00a0
\n \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | May 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2024 | \u00a0 | |||||
| Current assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 12 | \u00a0 | \u00a0 | $ | 95,720 | \u00a0 | \u00a0 | $ | 3 | \u00a0 | \u00a0 | $ | 95,735 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 124,675 | \u00a0 | \u00a0 | \u00a0 | 3,637 | \u00a0 | \u00a0 | \u00a0 | 160,312 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (9 | ) | \u00a0 | \u00a0 | (130,945 | ) | \u00a0 | \u00a0 | (6,913 | ) | \u00a0 | \u00a0 | (137,867 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (24,482 | ) | \u00a0 | \u00a0 | (1,452 | ) | \u00a0 | \u00a0 | (25,934 | ) |
| Net assets | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 3 | \u00a0 | \u00a0 | $ | 64,968 | \u00a0 | \u00a0 | $ | (4,725 | ) | \u00a0 | $ | 92,246 | \u00a0 |
\u00a0
\n \n \nThe following table provides a summary of certain income statement information before intercompany eliminations relating to the above referenced majority-owned subsidiaries of the Company in which there is a non-controlling interest\u00a0for the six months ended November 30, 2024:
\n\u00a0
\n \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | November 30, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2024 | \u00a0 | |||||
| Revenue | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 36,429 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 36,429 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 5 | \u00a0 | \u00a0 | \u00a0 | 26,919 | \u00a0 | \u00a0 | \u00a0 | 793 | \u00a0 | \u00a0 | \u00a0 | 27,717 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (5 | ) | \u00a0 | \u00a0 | 9,510 | \u00a0 | \u00a0 | \u00a0 | (793 | ) | \u00a0 | \u00a0 | 8,712 | \u00a0 |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1 | ) | \u00a0 | \u00a0 | (796 | ) | \u00a0 | \u00a0 | 434 | \u00a0 | \u00a0 | \u00a0 | (363 | ) |
| Net comprehensive (loss) income | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (6 | ) | \u00a0 | $ | 8,714 | \u00a0 | \u00a0 | $ | (359 | ) | \u00a0 | $ | 8,349 | \u00a0 |
| Non-controlling interest % | \u00a0 | \u00a0 | 32 | % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (2 | ) | \u00a0 | \u00a0 | 4,270 | \u00a0 | \u00a0 | \u00a0 | (36 | ) | \u00a0 | \u00a0 | 4,232 | \u00a0 |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (2 | ) | \u00a0 | $ | 4,270 | \u00a0 | \u00a0 | $ | (36 | ) | \u00a0 | $ | 4,232 | \u00a0 |
\u00a0
\nThe following table provides a summary of certain income statement information before intercompany eliminations relating to the above referenced majority-owned subsidiaries of the Company in which there is a non-controlling interest\u00a0for the six months ended November 30,\u00a02023:
\n\u00a0
\n \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | November 30, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2023 | \u00a0 | |||||
| Revenue | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 57,078 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 57,078 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 54 | \u00a0 | \u00a0 | \u00a0 | 32,803 | \u00a0 | \u00a0 | \u00a0 | (519 | ) | \u00a0 | \u00a0 | 32,338 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (54 | ) | \u00a0 | \u00a0 | 24,275 | \u00a0 | \u00a0 | \u00a0 | 519 | \u00a0 | \u00a0 | \u00a0 | 24,740 | \u00a0 |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (30 | ) | \u00a0 | \u00a0 | 404 | \u00a0 | \u00a0 | \u00a0 | (222 | ) | \u00a0 | \u00a0 | 152 | \u00a0 |
| Net comprehensive (loss) income | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (84 | ) | \u00a0 | $ | 24,679 | \u00a0 | \u00a0 | $ | 297 | \u00a0 | \u00a0 | $ | 24,892 | \u00a0 |
| Non-controlling interest % | \u00a0 | \u00a0 | 32 | % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (21 | ) | \u00a0 | \u00a0 | 12,093 | \u00a0 | \u00a0 | \u00a0 | 30 | \u00a0 | \u00a0 | \u00a0 | 12,102 | \u00a0 |
| Additional income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 6,554 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 6,554 | \u00a0 |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (21 | ) | \u00a0 | $ | 18,647 | \u00a0 | \u00a0 | $ | 30 | \u00a0 | \u00a0 | $ | 18,656 | \u00a0 |
\u00a0 \u00a0 \u00a0\u00a0
\n "}]},{"name":"rpt:f-1155","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:SuperheroAcquisitionLPMember"},"factValues":[{"value":"0.68","decimals":2}]},{"name":"rpt:f-1156","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:CCPharmaNordicApSMember"},"factValues":[{"value":"0.75","decimals":2}]},{"name":"rpt:f-1157","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:AphriaDiamondMember"},"factValues":[{"value":"0.51","decimals":2}]},{"name":"rpt:f-1158","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:ColCannaSASMember"},"factValues":[{"value":"0.90","decimals":1}]},{"name":"rpt:f-1159","factDimensions":{"xbrl:concept":"srt:ScheduleOfCondensedBalanceSheetTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | November 30, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2024 | \u00a0 | |||||
| Current assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 14 | \u00a0 | \u00a0 | $ | 57,936 | \u00a0 | \u00a0 | $ | 49 | \u00a0 | \u00a0 | $ | 57,999 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | 116,314 | \u00a0 | \u00a0 | \u00a0 | 3,213 | \u00a0 | \u00a0 | \u00a0 | 151,527 | \u00a0 | |
| Current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (17 | ) | \u00a0 | \u00a0 | (123,533 | ) | \u00a0 | \u00a0 | (6,894 | ) | \u00a0 | \u00a0 | (130,444 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | (25,095 | ) | \u00a0 | \u00a0 | (1,452 | ) | \u00a0 | \u00a0 | (26,547 | ) | |
| Net assets | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | (3 | ) | \u00a0 | $ | 25,622 | \u00a0 | \u00a0 | $ | (5,084 | ) | \u00a0 | $ | 52,535 | \u00a0 |
| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | May 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2024 | \u00a0 | |||||
| Current assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 12 | \u00a0 | \u00a0 | $ | 95,720 | \u00a0 | \u00a0 | $ | 3 | \u00a0 | \u00a0 | $ | 95,735 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 124,675 | \u00a0 | \u00a0 | \u00a0 | 3,637 | \u00a0 | \u00a0 | \u00a0 | 160,312 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (9 | ) | \u00a0 | \u00a0 | (130,945 | ) | \u00a0 | \u00a0 | (6,913 | ) | \u00a0 | \u00a0 | (137,867 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (24,482 | ) | \u00a0 | \u00a0 | (1,452 | ) | \u00a0 | \u00a0 | (25,934 | ) |
| Net assets | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 3 | \u00a0 | \u00a0 | $ | 64,968 | \u00a0 | \u00a0 | $ | (4,725 | ) | \u00a0 | $ | 92,246 | \u00a0 |
| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | November 30, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2024 | \u00a0 | |||||
| Revenue | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 36,429 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 36,429 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 5 | \u00a0 | \u00a0 | \u00a0 | 26,919 | \u00a0 | \u00a0 | \u00a0 | 793 | \u00a0 | \u00a0 | \u00a0 | 27,717 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (5 | ) | \u00a0 | \u00a0 | 9,510 | \u00a0 | \u00a0 | \u00a0 | (793 | ) | \u00a0 | \u00a0 | 8,712 | \u00a0 |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1 | ) | \u00a0 | \u00a0 | (796 | ) | \u00a0 | \u00a0 | 434 | \u00a0 | \u00a0 | \u00a0 | (363 | ) |
| Net comprehensive (loss) income | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (6 | ) | \u00a0 | $ | 8,714 | \u00a0 | \u00a0 | $ | (359 | ) | \u00a0 | $ | 8,349 | \u00a0 |
| Non-controlling interest % | \u00a0 | \u00a0 | 32 | % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (2 | ) | \u00a0 | \u00a0 | 4,270 | \u00a0 | \u00a0 | \u00a0 | (36 | ) | \u00a0 | \u00a0 | 4,232 | \u00a0 |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (2 | ) | \u00a0 | $ | 4,270 | \u00a0 | \u00a0 | $ | (36 | ) | \u00a0 | $ | 4,232 | \u00a0 |
| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | November 30, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2023 | \u00a0 | |||||
| Revenue | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 57,078 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 57,078 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 54 | \u00a0 | \u00a0 | \u00a0 | 32,803 | \u00a0 | \u00a0 | \u00a0 | (519 | ) | \u00a0 | \u00a0 | 32,338 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (54 | ) | \u00a0 | \u00a0 | 24,275 | \u00a0 | \u00a0 | \u00a0 | 519 | \u00a0 | \u00a0 | \u00a0 | 24,740 | \u00a0 |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (30 | ) | \u00a0 | \u00a0 | 404 | \u00a0 | \u00a0 | \u00a0 | (222 | ) | \u00a0 | \u00a0 | 152 | \u00a0 |
| Net comprehensive (loss) income | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (84 | ) | \u00a0 | $ | 24,679 | \u00a0 | \u00a0 | $ | 297 | \u00a0 | \u00a0 | $ | 24,892 | \u00a0 |
| Non-controlling interest % | \u00a0 | \u00a0 | 32 | % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (21 | ) | \u00a0 | \u00a0 | 12,093 | \u00a0 | \u00a0 | \u00a0 | 30 | \u00a0 | \u00a0 | \u00a0 | 12,102 | \u00a0 |
| Additional income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 6,554 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 6,554 | \u00a0 |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (21 | ) | \u00a0 | $ | 18,647 | \u00a0 | \u00a0 | $ | 30 | \u00a0 | \u00a0 | $ | 18,656 | \u00a0 |
Note 18. Income taxes
\n\u00a0
\nThe determination of the Company\u2019s overall effective\u00a0tax\u00a0rate requires significant judgment, the use of estimates, and the interpretation and application of complex\u00a0tax\u00a0laws. The effective\u00a0tax\u00a0rate reflects the income earned and taxed in various United States federal, state, and foreign jurisdictions.\u00a0Tax\u00a0law changes, increases, and decreases in temporary and permanent differences between book and\u00a0tax\u00a0items, valuation allowances against the deferred tax assets, stock compensation, and the Company\u2019s change in income in each jurisdiction all affect the overall effective\u00a0tax\u00a0rate. It is the Company\u2019s practice to recognize interest and penalties related to uncertain\u00a0tax\u00a0positions in income\u00a0tax\u00a0expense.
\n\u00a0
\nThe Company reported income tax expense of $2,036\u00a0and $2,922 for the three and six months ended November 30, 2024, and\u00a0income tax (recovery) expense of $(3,380) and $3,884 for the three and six months ended November 30,\u00a02023. The income tax benefit\u00a0in the current period varies from the US statutory income tax rate and prior period primarily due to the geographical mix of earnings and losses with no tax benefit resulting from valuation allowances in certain jurisdictions.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1295","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExpenseBenefit","xbrl:period":"2024-09-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2036000","decimals":-3}]},{"name":"rpt:f-1296","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExpenseBenefit","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2922000","decimals":-3}]},{"name":"rpt:f-1297","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExpenseBenefit","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"-3380000","decimals":-4}]},{"name":"rpt:f-1298","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExpenseBenefit","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3884000","decimals":-3}]},{"name":"rpt:f-1299","factDimensions":{"xbrl:concept":"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 19. Commitments and contingencies
\n\u00a0
\nPurchase and other commitments
\n\u00a0
\nThe Company has financial commitments\u00a0on long-term debt, refer to Note 12\u00a0(Long-term debt), convertible notes, refer to Note 13\u00a0(Convertible debentures payable), material purchase commitments and construction commitments as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Total | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2027 | \u00a0 | \u00a0 | 2028 | \u00a0 | \u00a0 | Thereafter | \u00a0 | ||||||
| Long-term debt repayment | \u00a0 | $ | 165,514 | \u00a0 | \u00a0 | $ | 15,838 | \u00a0 | \u00a0 | $ | 36,201 | \u00a0 | \u00a0 | $ | 12,103 | \u00a0 | \u00a0 | $ | 69,104 | \u00a0 | \u00a0 | $ | 32,268 | \u00a0 |
| Convertible debentures payable | \u00a0 | \u00a0 | 156,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 156,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Material purchase obligations | \u00a0 | \u00a0 | 63,615 | \u00a0 | \u00a0 | \u00a0 | 35,378 | \u00a0 | \u00a0 | \u00a0 | 28,237 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | |
| Construction commitments | \u00a0 | \u00a0 | 1,078 | \u00a0 | \u00a0 | \u00a0 | 1,078 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total | \u00a0 | $ | 386,207 | \u00a0 | \u00a0 | $ | 52,294 | \u00a0 | \u00a0 | $ | 64,438 | \u00a0 | \u00a0 | $ | 168,103 | \u00a0 | \u00a0 | $ | 69,104 | \u00a0 | \u00a0 | $ | 32,268 | \u00a0 |
\u00a0
\nLegal proceedings
\n\u00a0
\nIn the ordinary course of business, we are at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves\u00a0 may\u00a0be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is\u00a0not\u00a0probable or the amount of loss is\u00a0not\u00a0estimable, we do\u00a0not\u00a0accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available and available insurance coverage, our management believes that it has established appropriate legal reserves. Any incremental liabilities arising from pending legal proceedings are\u00a0not\u00a0expected to have a material adverse effect on our consolidated financial position, consolidated results of operations, or consolidated cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable,\u00a0 may\u00a0be material to our consolidated financial position, consolidated results of operations, or consolidated cash flows.
\n\u00a0
\nThere have been no material changes in\u00a0the legal proceedings since\u00a0our Annual Report on Form 10-K\u00a0for the fiscal year ended May 31, 2024, except with respect to the legal proceedings disclosed below:
\n\u00a0
\nAuthentic Brands Group Related Class Action (New York, United States)
\n\u00a0
\nOn May 4, 2020, Ganesh Kasilingam filed a lawsuit in the United States District Court for the Southern District of New York (\u201cSDNY\u201d), against Tilray Brands, Inc., Brendan Kennedy and Mark Castaneda, on behalf of himself and a putative class, seeking to recover damages for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the \u201cKasilingam litigation\u201d). The complaint alleges that Tilray and the individual defendants overstated the anticipated advantages of the Company\u2019s revenue sharing agreement with Authentic Brands Group (\u201cABG\u201d), announced on January 15, 2019, and that the plaintiff suffered losses when Tilray\u2019s stock price dropped after Tilray recognized an impairment with respect to the ABG deal on March 2, 2020.
\n\u00a0
\nOn September 27, 2021, the U.S. District Court entered an Opinion & Order granting the Defendants\u2019 motion to dismiss the complaint in the Kasilingam litigation without prejudice. On December 3, 2021, the lead plaintiff filed a second amended complaint alleging similar claims against Tilray and Brendan Kennedy. The Defendants successfully moved to dismiss the second amended complaint on February 2, 2022. In dismissing the second amended complaint, the court granted the Plaintiff leave to amend one final time. On September 27, 2023, the Plaintiff filed its Third Amended Complaint.
\n\u00a0
\nOn September 30, 2024, the U.S. District Court entered an Opinion & Order granting the Defendants\u2019 motion to dismiss the Third Amended Complaint in the Kasilingam litigation with prejudice.\u00a0
\n\u00a0
\nIn the Matter of an Arbitration Between: K. Dickson v. Tilray, Inc.
\n\u00a0
\nIn 2021, Ms. Dickson, the former President of Manitoba Harvest, a wholly-owned subsidiary of Tilray, commenced an arbitration in Minneapolis, Minnesota against Tilray, alleging that Tilray materially breached her Employment Agreement with Tilray and asserted certain Washington statutory wage claims.
\n\u00a0
\nOn March 17, 2023, the arbitrator awarded Dickson $3,734 in damages, plus amounts for pre-judgment, and double damages under a Washington state wage payment statute (the \u201cArbitration Award\u201d). Tilray\u2019s counterclaim was denied by the Arbitrator. On May 23, 2023, the arbitrator issued a supplemental award which provided that Dickson was entitled to recover attorney fees and costs from Tilray in connection with the arbitration.\u00a0 On February 27, 2024, the U.S. District Court for the Western District of Washington dismissed as moot Tilray\u2019s petition to vacate, modify or correct the Arbitration Award, granting Dickson\u2019s responding motion to dismiss on the basis that the U.S. District Court for the Western District of Washington lacked personal jurisdiction over Dickson. On March 15, 2024, Tilray filed its notice of appeal of the decision of the U.S. District Court for the Western District of Washington to the U.S. Court of Appeals for the Ninth Circuit. On August 8, 2024, the District Court in Minnesota confirmed the Arbitration Award. A judgment on the Arbitration Award was entered by the Court on August 12, 2024, and, following a motion by Dickson to correct the judgment, became final on September 27, 2024.\u00a0Tilray\u00a0filed a notice of appeal to the U.S. Court of Appeals for the Eighth Circuit.\u00a0In October 2024, the parties entered into a settlement agreement and Tilray paid Dickson the amount of the Arbitration Award, concluding the litigation.
\n\u00a0
\nNabil Salama v. Tilray Brands, Inc., et. al
\n\u00a0
\nOn November 6, 2024, Tilray disclosed in a Current Report on Form 8-K that a lawsuit was commenced against it and its directors, captioned Nabil Salama v. Tilray Brands, Inc., et. al (C.A. No. 2024-1124-JTL).
\n\u00a0
\nThis lawsuit was filed on October 31, 2024 on behalf of a putative class of stockholders and alleged that (a) Tilray\u2019s definitive proxy statement for its 2024 Annual Meeting of Stockholders (the \u201c2024 Proxy Statement\u201d) incorrectly applied a majority-of-votes-cast voting standard for approval of the proposal to increase the number of shares of Common Stock authorized for issuance (the \u201c2024 Authorized Shares Proposal\u201d), (b) the proposal increasing the number of shares of Common Stock authorized for issuance (the \u201c2023 Authorized Shares Proposal\u201d and together with the 2024 Authorized Shares Proposal, the \u201cAuthorized Shares Proposals\u201d) was not validly approved by the stockholders under a majority-of-votes-cast voting standard, and any related issuances of Common Stock were and are not validly authorized, and (c) the named directors of Tilray have breached their fiduciary duties by failing to make accurate disclosures regarding the Authorized Shares Proposals in the 2024 Proxy Statement and 2023 Proxy Statement.
\n\u00a0
\nOn November 27, 2024, the Court of Chancery of the State of Delaware ruled in favor of Tilray and granted summary judgment for Tilray and its directors. Specifically, the Court held that Tilray correctly applied a majority-of-votes-cast voting standard to its Authorized Shares Proposals.
\n\u00a0
\nOn December 4, 2024, Plaintiff filed a notice of appeal from the Court\u2019s order granting summary judgment. Tilray intends to contest this appeal, which it believes to be without merit.\u00a0
\n\u00a0
\nSummary of litigation accruals\u00a0
\n\u00a0
\nAs described in Note 11\u00a0(Accounts payable and accrued liabilities), the total estimated litigation\u00a0expense accrual included in accrued liabilities as of\u00a0 November 30, 2024\u00a0and May 31, 2024 was\u00a0$19,610. and\u00a0$24,378\u00a0respectively. This estimated accrual is intended to cover various ongoing litigation matters with probable losses that can be reasonably estimated.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1300","factDimensions":{"xbrl:concept":"srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | Total | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2027 | \u00a0 | \u00a0 | 2028 | \u00a0 | \u00a0 | Thereafter | \u00a0 | ||||||
| Long-term debt repayment | \u00a0 | $ | 165,514 | \u00a0 | \u00a0 | $ | 15,838 | \u00a0 | \u00a0 | $ | 36,201 | \u00a0 | \u00a0 | $ | 12,103 | \u00a0 | \u00a0 | $ | 69,104 | \u00a0 | \u00a0 | $ | 32,268 | \u00a0 |
| Convertible debentures payable | \u00a0 | \u00a0 | 156,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 156,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Material purchase obligations | \u00a0 | \u00a0 | 63,615 | \u00a0 | \u00a0 | \u00a0 | 35,378 | \u00a0 | \u00a0 | \u00a0 | 28,237 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | |
| Construction commitments | \u00a0 | \u00a0 | 1,078 | \u00a0 | \u00a0 | \u00a0 | 1,078 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total | \u00a0 | $ | 386,207 | \u00a0 | \u00a0 | $ | 52,294 | \u00a0 | \u00a0 | $ | 64,438 | \u00a0 | \u00a0 | $ | 168,103 | \u00a0 | \u00a0 | $ | 69,104 | \u00a0 | \u00a0 | $ | 32,268 | \u00a0 |
Note 20. Net revenue
\n\u00a0
\nThe Company reports Net revenue in\u00a0four\u00a0reporting segments: beverage, cannabis, distribution, and wellness. Net Revenue for the\u00a0three and six months ended November 30, 2024\u00a0and November 30, 2023 were as follows:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \n For the three months ended | \n \u00a0 | \n\u00a0 | \n For the six months ended | \n \u00a0 | \n||||||||||
| \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n||||
| \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n||||
| Beverage revenue | \n \u00a0 | \n$ | \n66,861 | \n\u00a0 | \n\u00a0 | \n$ | \n49,651 | \n\u00a0 | \n\u00a0 | \n$ | \n126,024 | \n\u00a0 | \n\u00a0 | \n$ | \n74,990 | \n\u00a0 | \n
| Beverage excise taxes | \n \u00a0 | \n\u00a0 | \n(3,780 | \n) | \n\u00a0 | \n\u00a0 | \n(3,146 | \n) | \n\u00a0 | \n\u00a0 | \n(6,971 | \n) | \n\u00a0 | \n\u00a0 | \n(4,323 | \n) | \n
| Net beverage revenue | \n \u00a0 | \n\u00a0 | \n63,081 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n46,505 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n119,053 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n70,667 | \n\u00a0 | \n
| Cannabis revenue | \n \u00a0 | \n\u00a0 | \n87,208 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n94,556 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n168,402 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n191,440 | \n\u00a0 | \n
| Cannabis excise taxes | \n \u00a0 | \n\u00a0 | \n(21,556 | \n) | \n\u00a0 | \n\u00a0 | \n(27,442 | \n) | \n\u00a0 | \n\u00a0 | \n(41,501 | \n) | \n\u00a0 | \n\u00a0 | \n(53,993 | \n) | \n
| Net cannabis revenue | \n \u00a0 | \n\u00a0 | \n65,652 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n67,114 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n126,901 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n137,447 | \n\u00a0 | \n
| Distribution revenue | \n \u00a0 | \n\u00a0 | \n67,611 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n67,223 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n135,682 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n136,380 | \n\u00a0 | \n
| Wellness revenue | \n \u00a0 | \n\u00a0 | \n14,606 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n12,929 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n29,358 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n26,226 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n210,950 | \n\u00a0 | \n\u00a0 | \n$ | \n193,771 | \n\u00a0 | \n\u00a0 | \n$ | \n410,994 | \n\u00a0 | \n\u00a0 | \n$ | \n370,720 | \n\u00a0 | \n
\u00a0\u00a0
\n "}]},{"name":"rpt:f-1335","factDimensions":{"xbrl:concept":"us-gaap:NumberOfReportableSegments","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"4"}]},{"name":"rpt:f-1336","factDimensions":{"xbrl:concept":"us-gaap:DisaggregationOfRevenueTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \n For the three months ended | \n \u00a0 | \n\u00a0 | \n For the six months ended | \n \u00a0 | \n||||||||||
| \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n||||
| \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n||||
| Beverage revenue | \n \u00a0 | \n$ | \n66,861 | \n\u00a0 | \n\u00a0 | \n$ | \n49,651 | \n\u00a0 | \n\u00a0 | \n$ | \n126,024 | \n\u00a0 | \n\u00a0 | \n$ | \n74,990 | \n\u00a0 | \n
| Beverage excise taxes | \n \u00a0 | \n\u00a0 | \n(3,780 | \n) | \n\u00a0 | \n\u00a0 | \n(3,146 | \n) | \n\u00a0 | \n\u00a0 | \n(6,971 | \n) | \n\u00a0 | \n\u00a0 | \n(4,323 | \n) | \n
| Net beverage revenue | \n \u00a0 | \n\u00a0 | \n63,081 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n46,505 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n119,053 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n70,667 | \n\u00a0 | \n
| Cannabis revenue | \n \u00a0 | \n\u00a0 | \n87,208 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n94,556 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n168,402 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n191,440 | \n\u00a0 | \n
| Cannabis excise taxes | \n \u00a0 | \n\u00a0 | \n(21,556 | \n) | \n\u00a0 | \n\u00a0 | \n(27,442 | \n) | \n\u00a0 | \n\u00a0 | \n(41,501 | \n) | \n\u00a0 | \n\u00a0 | \n(53,993 | \n) | \n
| Net cannabis revenue | \n \u00a0 | \n\u00a0 | \n65,652 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n67,114 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n126,901 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n137,447 | \n\u00a0 | \n
| Distribution revenue | \n \u00a0 | \n\u00a0 | \n67,611 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n67,223 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n135,682 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n136,380 | \n\u00a0 | \n
| Wellness revenue | \n \u00a0 | \n\u00a0 | \n14,606 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n12,929 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n29,358 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n26,226 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n210,950 | \n\u00a0 | \n\u00a0 | \n$ | \n193,771 | \n\u00a0 | \n\u00a0 | \n$ | \n410,994 | \n\u00a0 | \n\u00a0 | \n$ | \n370,720 | \n\u00a0 | \n
Note 21. Cost of goods sold
\n\u00a0
\nThe Company reports Cost of goods sold in\u00a0four\u00a0reporting segments: beverage, cannabis, distribution, and wellness.\u00a0Cost of goods sold for the\u00a0three and six months ended November 30, 2024\u00a0and November 30, 2023 were as follows:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \n For the three months ended | \n \u00a0 | \n\u00a0 | \n For the six months ended | \n \u00a0 | \n||||||||||
| \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n||||
| \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n||||
| Beverage costs | \n \u00a0 | \n\u00a0 | \n37,925 | \n\u00a0 | \n\u00a0 | \n$ | \n30,513 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n70,975 | \n\u00a0 | \n\u00a0 | \n$ | \n41,779 | \n\u00a0 | \n
| Cannabis costs | \n \u00a0 | \n\u00a0 | \n42,475 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n46,472 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n79,529 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n96,989 | \n\u00a0 | \n
| Distribution costs | \n \u00a0 | \n\u00a0 | \n59,207 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n60,147 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n119,345 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n121,615 | \n\u00a0 | \n
| Wellness costs | \n \u00a0 | \n\u00a0 | \n10,123 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n9,230 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n20,219 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n18,732 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n149,730 | \n\u00a0 | \n\u00a0 | \n$ | \n146,362 | \n\u00a0 | \n\u00a0 | \n$ | \n290,068 | \n\u00a0 | \n\u00a0 | \n$ | \n279,115 | \n\u00a0 | \n
\u00a0 \u00a0 \u00a0
\n "}]},{"name":"rpt:f-1374","factDimensions":{"xbrl:concept":"us-gaap:NumberOfReportableSegments","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"4"}]},{"name":"rpt:f-1375","factDimensions":{"xbrl:concept":"tlry:ScheduleOfCostOfGoodsSoldTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \n For the three months ended | \n \u00a0 | \n\u00a0 | \n For the six months ended | \n \u00a0 | \n||||||||||
| \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n||||
| \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n||||
| Beverage costs | \n \u00a0 | \n\u00a0 | \n37,925 | \n\u00a0 | \n\u00a0 | \n$ | \n30,513 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n70,975 | \n\u00a0 | \n\u00a0 | \n$ | \n41,779 | \n\u00a0 | \n
| Cannabis costs | \n \u00a0 | \n\u00a0 | \n42,475 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n46,472 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n79,529 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n96,989 | \n\u00a0 | \n
| Distribution costs | \n \u00a0 | \n\u00a0 | \n59,207 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n60,147 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n119,345 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n121,615 | \n\u00a0 | \n
| Wellness costs | \n \u00a0 | \n\u00a0 | \n10,123 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n9,230 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n20,219 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n18,732 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n149,730 | \n\u00a0 | \n\u00a0 | \n$ | \n146,362 | \n\u00a0 | \n\u00a0 | \n$ | \n290,068 | \n\u00a0 | \n\u00a0 | \n$ | \n279,115 | \n\u00a0 | \n
Note 22. General and administrative expenses
\n\u00a0
\nGeneral and administrative expenses\u00a0for the\u00a0three and six months ended November 30, 2024\u00a0and November 30, 2023 were as follows:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \n For the three months ended | \n \u00a0 | \n\u00a0 | \n For the six months ended | \n \u00a0 | \n||||||||||
| \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n||||
| \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n||||
| Salaries and wages | \n \u00a0 | \n$ | \n22,726 | \n\u00a0 | \n\u00a0 | \n$ | \n19,119 | \n\u00a0 | \n\u00a0 | \n$ | \n44,293 | \n\u00a0 | \n\u00a0 | \n$ | \n35,894 | \n\u00a0 | \n
| Office and general | \n \u00a0 | \n\u00a0 | \n9,458 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n8,065 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n18,718 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n16,233 | \n\u00a0 | \n
| Stock-based compensation | \n \u00a0 | \n\u00a0 | \n7,237 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n8,201 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n14,154 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n16,458 | \n\u00a0 | \n
| Insurance | \n \u00a0 | \n\u00a0 | \n3,155 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,499 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n5,610 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n6,348 | \n\u00a0 | \n
| Professional fees | \n \u00a0 | \n\u00a0 | \n1,126 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,503 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,304 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,002 | \n\u00a0 | \n
| (Gain) loss on sale of capital assets | \n \u00a0 | \n\u00a0 | \n(505 | \n) | \n\u00a0 | \n\u00a0 | \n(23 | \n) | \n\u00a0 | \n\u00a0 | \n(531 | \n) | \n\u00a0 | \n\u00a0 | \n(20 | \n) | \n
| Travel and accommodation | \n \u00a0 | \n\u00a0 | \n1,754 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n1,374 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n3,247 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,481 | \n\u00a0 | \n
| Rent | \n \u00a0 | \n\u00a0 | \n1,046 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n1,575 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,315 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,433 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n45,997 | \n\u00a0 | \n\u00a0 | \n$ | \n43,313 | \n\u00a0 | \n\u00a0 | \n$ | \n90,110 | \n\u00a0 | \n\u00a0 | \n$ | \n83,829 | \n\u00a0 | \n
\u00a0
\n \n \n "}]},{"name":"rpt:f-1397","factDimensions":{"xbrl:concept":"tlry:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \n For the three months ended | \n \u00a0 | \n\u00a0 | \n For the six months ended | \n \u00a0 | \n||||||||||
| \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n\u00a0 | \n November 30, | \n \u00a0 | \n||||
| \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2023 | \n \u00a0 | \n||||
| Salaries and wages | \n \u00a0 | \n$ | \n22,726 | \n\u00a0 | \n\u00a0 | \n$ | \n19,119 | \n\u00a0 | \n\u00a0 | \n$ | \n44,293 | \n\u00a0 | \n\u00a0 | \n$ | \n35,894 | \n\u00a0 | \n
| Office and general | \n \u00a0 | \n\u00a0 | \n9,458 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n8,065 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n18,718 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n16,233 | \n\u00a0 | \n
| Stock-based compensation | \n \u00a0 | \n\u00a0 | \n7,237 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n8,201 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n14,154 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n16,458 | \n\u00a0 | \n
| Insurance | \n \u00a0 | \n\u00a0 | \n3,155 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,499 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n5,610 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n6,348 | \n\u00a0 | \n
| Professional fees | \n \u00a0 | \n\u00a0 | \n1,126 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,503 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,304 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,002 | \n\u00a0 | \n
| (Gain) loss on sale of capital assets | \n \u00a0 | \n\u00a0 | \n(505 | \n) | \n\u00a0 | \n\u00a0 | \n(23 | \n) | \n\u00a0 | \n\u00a0 | \n(531 | \n) | \n\u00a0 | \n\u00a0 | \n(20 | \n) | \n
| Travel and accommodation | \n \u00a0 | \n\u00a0 | \n1,754 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n1,374 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n3,247 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,481 | \n\u00a0 | \n
| Rent | \n \u00a0 | \n\u00a0 | \n1,046 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n1,575 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,315 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n2,433 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n45,997 | \n\u00a0 | \n\u00a0 | \n$ | \n43,313 | \n\u00a0 | \n\u00a0 | \n$ | \n90,110 | \n\u00a0 | \n\u00a0 | \n$ | \n83,829 | \n\u00a0 | \n
Note 23. Restructuring charges
\n\u00a0
\nIn connection with the execution of our acquisition strategy and strategic transactions, the Company has incurred restructuring and exit costs associated with the integration efforts of these transactions. In connection with these efforts, the Company recognized $6,869\u00a0and $11,116 of restructuring charges for the three and six months ended November 30, 2024\u00a0compared to $2,655\u00a0and $3,570 for the prior year period. All restructuring\u00a0plans are approved at the executive level, and their associated expenses are recognized in\u00a0the period in which the plan is\u00a0committed. All amounts incurred as of\u00a0 November 30, 2024\u00a0have been paid.\u00a0
\n\u00a0
\nWithin the Cannabis segment, our restructuring costs predominantly related to\u00a0the\u00a0HEXO acquisition, which are expected to be completed within 24 months from the original acquisition, which occurred June 2023. In the six months ended November 30, 2024, we\u00a0recognized\u00a0$5,892 of expenses related to employee termination severance and benefits and other costs related to\u00a0the conversion of the HEXO Quebec cultivation facility from cannabis to produce (which is currently held for sale),\u00a0the optimization of our Redecan facilities, and\u00a0$619 of restructuring charges related to the remaining costs of exiting the Truss facility following its sale to a third party in the fiscal year ended May 31, 2024. Additionally, the Company recognized $357\u00a0of cost associated winding down the Fort Collins warehouse (which is currently held for sale), and $649 of cost associated with the winding down of our Avanti facility, the closure of which was announced during the quarter ended\u00a0 November 30, 2024.\u00a0
\n\u00a0
\nWithin the beverage\u00a0segment, the Company recognized\u00a0$990\u00a0of expenses related to employee termination severance and benefits and\u00a0$791 of costs associated with the consolidation\u00a0of production sites\u00a0through the integration of the Craft Acquisition and the Craft Acquisition II. Additionally, the Company recognized $500 of restructuring charges related to terminating a legacy storage\u00a0agreement from the Craft Acquisition. We expect to transition to a new storage facility\u00a0in the fourth quarter of fiscal year May 31, 2025.\u00a0
\n\u00a0
\nWithin the distribution segment, the Company recognized $234\u00a0of restructuring charges related to the divestiture of\u00a0its retail pharmacy location in Argentina.\u00a0
\n\u00a0
\nLastly, for the\u00a0three and six months ended November 30, 2024, the Company recognized $1,084 of costs associated with the investment held in Superhero Acquisition Corp.\u00a0as a result of MedMen\u2019s ongoing restructuring and\u00a0liquidation undertakings.
\n\u00a0
\n "}]},{"name":"rpt:f-1435","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-09-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"6869000","decimals":-3}]},{"name":"rpt:f-1436","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"11116000","decimals":-3}]},{"name":"rpt:f-1437","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2023-09-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"2655000","decimals":-3}]},{"name":"rpt:f-1438","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2023-06-01T00:00:00/2023-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"3570000","decimals":-4}]},{"name":"rpt:f-1439","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:HexoAcquisitionMember","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:EmployeeSeveranceMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:CannabisSegmentMember"},"factValues":[{"value":"5892000","decimals":-3}]},{"name":"rpt:f-1440","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis":"tlry:TrussBeverageCompanyMember","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:FacilityClosingMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:CannabisSegmentMember"},"factValues":[{"value":"619000","decimals":-3}]},{"name":"rpt:f-1441","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"tlry:FortCollinsFacilityMember","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:FacilityClosingMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:CannabisSegmentMember"},"factValues":[{"value":"357000","decimals":-3}]},{"name":"rpt:f-1442","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"tlry:AvantiFacilityMember","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:FacilityClosingMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:CannabisSegmentMember"},"factValues":[{"value":"649000","decimals":-3}]},{"name":"rpt:f-1443","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:EmployeeSeveranceMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:BeverageSegmentMember"},"factValues":[{"value":"990000","decimals":-4}]},{"name":"rpt:f-1444","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:CraftAcquisitionAndCraftAcquisitionIIMember","us-gaap:RestructuringCostAndReserveAxis":"tlry:ConsolidationOfProductionSitesMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:BeverageSegmentMember"},"factValues":[{"value":"791000","decimals":-3}]},{"name":"rpt:f-1445","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:CraftAcquisitionAndCraftAcquisitionIIMember","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:ContractTerminationMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:BeverageSegmentMember"},"factValues":[{"value":"500000","decimals":-5}]},{"name":"rpt:f-1446","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:StatementBusinessSegmentsAxis":"tlry:DistributionBusinessMember"},"factValues":[{"value":"234000","decimals":-3}]},{"name":"rpt:f-1447","factDimensions":{"xbrl:concept":"us-gaap:RestructuringAndRelatedCostIncurredCost","xbrl:period":"2024-09-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:SuperheroLPMember"},"factValues":[{"value":"1084000","decimals":-3}]},{"name":"rpt:f-1448","factDimensions":{"xbrl:concept":"us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 24. Non-operating income (expense), net
\n\u00a0
\nNon-operating income (expense), net for the\u00a0three and six months ended November 30, 2024\u00a0and November 30, 2023 were as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the six months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||||
| Change in fair value of convertible debenture payable | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (3,894 | ) | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (6,041 | ) |
| Change in fair value of warrant liability | \u00a0 | \u00a0 | 862 | \u00a0 | \u00a0 | \u00a0 | 6,247 | \u00a0 | \u00a0 | \u00a0 | 1,558 | \u00a0 | \u00a0 | \u00a0 | (1,951 | ) |
| Foreign exchange gain (loss) | \u00a0 | \u00a0 | (33,797 | ) | \u00a0 | \u00a0 | (1,024 | ) | \u00a0 | \u00a0 | (21,916 | ) | \u00a0 | \u00a0 | 5,243 | \u00a0 |
| (Loss) gain on long-term investments | \u00a0 | \u00a0 | (27 | ) | \u00a0 | \u00a0 | 459 | \u00a0 | \u00a0 | \u00a0 | (66 | ) | \u00a0 | \u00a0 | 350 | \u00a0 |
| Other non-operating (losses) gains, net | \u00a0 | \u00a0 | (293 | ) | \u00a0 | \u00a0 | (967 | ) | \u00a0 | \u00a0 | (185 | ) | \u00a0 | \u00a0 | (1,182 | ) |
| Total | \u00a0 | $ | (33,255 | ) | \u00a0 | $ | 821 | \u00a0 | \u00a0 | $ | (20,609 | ) | \u00a0 | $ | (3,581 | ) |
\u00a0
\nThe other non-operating (losses) gains, net for the\u00a0three and six months ended November 30, 2024, were\u00a0losses of ($293) and ($185), respectively. The other non-operating (losses) gains, net were mainly\u00a0comprised of\u00a0a gain\u00a0of $679 resulting from the exchange transaction of\u00a0the TLRY 27 Note, see Note 17\u00a0(Convertible debentures payable)\u00a0and\u00a0a loss of ($950) to settle outstanding notes with the non-controlling interest shareholder.
\n\u00a0
\n "}]},{"name":"rpt:f-1449","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the six months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||||
| Change in fair value of convertible debenture payable | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (3,894 | ) | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (6,041 | ) |
| Change in fair value of warrant liability | \u00a0 | \u00a0 | 862 | \u00a0 | \u00a0 | \u00a0 | 6,247 | \u00a0 | \u00a0 | \u00a0 | 1,558 | \u00a0 | \u00a0 | \u00a0 | (1,951 | ) |
| Foreign exchange gain (loss) | \u00a0 | \u00a0 | (33,797 | ) | \u00a0 | \u00a0 | (1,024 | ) | \u00a0 | \u00a0 | (21,916 | ) | \u00a0 | \u00a0 | 5,243 | \u00a0 |
| (Loss) gain on long-term investments | \u00a0 | \u00a0 | (27 | ) | \u00a0 | \u00a0 | 459 | \u00a0 | \u00a0 | \u00a0 | (66 | ) | \u00a0 | \u00a0 | 350 | \u00a0 |
| Other non-operating (losses) gains, net | \u00a0 | \u00a0 | (293 | ) | \u00a0 | \u00a0 | (967 | ) | \u00a0 | \u00a0 | (185 | ) | \u00a0 | \u00a0 | (1,182 | ) |
| Total | \u00a0 | $ | (33,255 | ) | \u00a0 | $ | 821 | \u00a0 | \u00a0 | $ | (20,609 | ) | \u00a0 | $ | (3,581 | ) |
Note 25. Fair value measurements
\n\u00a0
\nFinancial instruments
\n\u00a0
\nThe Company's classification of its financial instruments are described in Note 3\u00a0(Significant accounting policies) in the Notes to our Annual Financial Statements.
\n\u00a0
\nThe carrying values of marketable securities, accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity.
\n\u00a0
\nOn\u00a0 November 30, 2024\u00a0and\u00a0 May 31, 2024, the Company had long-term debt of $2,950 and $3,568, respectively,\u00a0and the principal portion of convertible debentures payable of $156,000 and $172,830, respectively,\u00a0subject to fixed interest rates. The Company\u2019s long-term debt is valued based on discounting the future cash outflows associated with the long-term debt. The discount rate is based on the incremental premium above market rates for the U.S. Department of the Treasury securities of similar duration. In each period thereafter, the incremental premium is held constant while the U.S. Department of the Treasury security is based on the then current market value to derive the discount rate.
\n\u00a0
\n \n \nThe following tables present information about the Company\u2019s assets and liabilities that are measured at fair value on a recurring basis as of November 30, 2024 and\u00a0 May 31, 2024 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | November 30, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 189,698 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 189,698 | \u00a0 |
| Marketable securities | \u00a0 | \u00a0 | 62,551 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 62,551 | \u00a0 |
| Convertible notes receivable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | 935 | \u00a0 | \u00a0 | \u00a0 | 981 | \u00a0 | \u00a0 | \u00a0 | 5,500 | \u00a0 | \u00a0 | \u00a0 | 7,416 | \u00a0 |
| Financial liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Warrant liability | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1,695 | ) | \u00a0 | \u00a0 | (1,695 | ) |
| Contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (15,000 | ) | \u00a0 | \u00a0 | (15,000 | ) |
| APHA 24 Convertible debenture | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total recurring fair value measurements | \u00a0 | $ | 253,184 | \u00a0 | \u00a0 | $ | 981 | \u00a0 | \u00a0 | $ | 20,805 | \u00a0 | \u00a0 | $ | 274,970 | \u00a0 |
\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | May 31, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 228,340 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 228,340 | \u00a0 |
| Marketable securities | \u00a0 | \u00a0 | 32,182 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 32,182 | \u00a0 |
| Convertible notes receivable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | 919 | \u00a0 | \u00a0 | \u00a0 | 1,440 | \u00a0 | \u00a0 | \u00a0 | 5,500 | \u00a0 | \u00a0 | \u00a0 | 7,859 | \u00a0 |
| Financial liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Warrant liability | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (3,253 | ) | \u00a0 | \u00a0 | (3,253 | ) |
| Contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (15,000 | ) | \u00a0 | \u00a0 | (15,000 | ) |
| APHA 24 Convertible debenture | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (330 | ) | \u00a0 | \u00a0 | (330 | ) |
| Total recurring fair value measurements | \u00a0 | $ | 261,441 | \u00a0 | \u00a0 | $ | 1,440 | \u00a0 | \u00a0 | $ | 18,917 | \u00a0 | \u00a0 | $ | 281,798 | \u00a0 |
\u00a0
\nThe Company\u2019s financial assets and liabilities required to be measured on a recurring basis are its convertible notes receivable, equity investments measured at fair value, convertible debentures measured at fair value, acquisition-related contingent consideration, and warrant liability.
\n\u00a0
\nConvertible notes receivable and long-term investments are recorded at fair value. The estimated fair value is determined using, among\u00a0others,\u00a0the Black Scholes option pricing model, probability of legalization and is classified as Level\u00a03.
\n\u00a0
\nConvertible debentures payable are recorded at fair value when elected or required under US GAAP. Specifically, the APHA\u00a024\u00a0instrument's estimated fair value was\u00a0determined using the Black-Scholes option pricing model and was\u00a0classified as Level\u00a03.\u00a0
\n\u00a0
\nCertain equity investments recorded at fair value have quoted prices in active markets for identical assets and are classified as Level\u00a01. The\u00a0Company classified securities with observable inputs as Level\u00a02\u00a0and without a quoted market price as Level\u00a03.
\n\u00a0
\nThe warrants associated with the warrant liability are classified as Level\u00a03\u00a0derivatives. Consequently, the estimated fair value of the warrant liability is determined using the Black-Scholes pricing model. Until the warrants are exercised, expire, or other facts and circumstances lead the warrant liability to be reclassified to stockholders\u2019 equity, the warrant liability (which relates to warrants to purchase shares of Common Stock) is marked-to-market each reporting period with the change in fair value recorded as the\u00a0change in fair value of warrant liability within the consolidated statements of loss and comprehensive loss. Any significant adjustments to the unobservable inputs disclosed in the table below would have a direct impact on the fair value of the warrant liability.
\n\u00a0
\nA portion of the consideration to be paid in connection with the Company\u2019s acquisition\u00a0of Montauk Brewing is contingent upon the achievement of certain financial measures as of December 2025. If achieved, such contingent consideration is payable in cash. The contingent consideration amount\u00a0was estimated by applying a\u00a0probability of achievement of 100% on the $15,000 sales earn-out component and 0% on the remaining criteria, which is not expected to be achieved. The unobservable inputs into the future expected cash outflows result in a fair value measurement classified as Level\u00a03.
\n\u00a0
\nDuring the six months ended November 30, 2024,\u00a0a decrease in fair value of was recognized compared to a decrease of fair value of $10,584 in the period ended\u00a0 November 30, 2023 for the contingent consideration from the SweetWater acquisition as a result of not\u00a0achieving the incentive targets.\u00a0
\n\u00a0
\nThe balances of assets and liabilities categorized within Level\u00a03\u00a0of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows:
\n\u00a0
\n \n \n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | APHA 24 | \u00a0 | |
| \u00a0 | \u00a0 | Convertible | \u00a0 | \u00a0 | Equity | \u00a0 | \u00a0 | Warrant | \u00a0 | \u00a0 | Contingent | \u00a0 | \u00a0 | Convertible | \u00a0 | |||||
| \u00a0 | \u00a0 | notes receivable | \u00a0 | \u00a0 | Investments | \u00a0 | \u00a0 | Liability | \u00a0 | \u00a0 | Consideration | \u00a0 | \u00a0 | Debt | \u00a0 | |||||
| Balance, May 31, 2024 | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 5,500 | \u00a0 | \u00a0 | $ | (3,253 | ) | \u00a0 | $ | (15,000 | ) | \u00a0 | $ | (330 | ) |
| Additions/(Repayments) | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 330 | \u00a0 |
| Unrealized gain (loss) on fair value | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 1,558 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Balance, November 30, 2024 | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 5,500 | \u00a0 | \u00a0 | $ | (1,695 | ) | \u00a0 | $ | (15,000 | ) | \u00a0 | $ | \u2014 | \u00a0 |
\u00a0
\nThe unrealized gain (loss) on fair value for the convertible debenture, the warrant liability, contingent consideration, and debt securities classified under available-for-sale method is recognized in the consolidated statements of loss and comprehensive loss using the following inputs:
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | Significant | \u00a0 | \u00a0 | |
| \u00a0 | \u00a0 | Valuation | \u00a0 | unobservable | \u00a0 | \u00a0 | |
| Financial asset / financial liability | \u00a0 | technique | \u00a0 | input | \u00a0 | Inputs | \u00a0 |
| Warrant liability | \u00a0 | Black-Scholes | \u00a0 | Volatility, | \u00a0 | 50% | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | expected life (in years) | \u00a0 | 0.8 | \u00a0 |
| Contingent consideration | \u00a0 | Discounted cash flows | \u00a0 | Discount rate, | \u00a0 | 11% | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | Probability of achievement | \u00a0 |
| \u00a0 |
\u00a0
\nItems measured at fair value on a non-recurring basis
\n\u00a0
\nThe Company's prepaids and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.
\n\u00a0
\nManagement reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been no changes to the Company\u2019s capital management approach in the period. The Company considers its cash and cash equivalents and marketable securities as capital.
\n "}]},{"name":"rpt:f-1479","factDimensions":{"xbrl:concept":"us-gaap:LongtermDebtPercentageBearingFixedInterestAmount","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"tlry:LongtermDebtExcludingConvertibleDebenturesMember"},"factValues":[{"value":"2950000","decimals":-4}]},{"name":"rpt:f-1480","factDimensions":{"xbrl:concept":"us-gaap:LongtermDebtPercentageBearingFixedInterestAmount","xbrl:period":"2024-06-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"tlry:LongtermDebtExcludingConvertibleDebenturesMember"},"factValues":[{"value":"3568000","decimals":-3}]},{"name":"rpt:f-1481","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebt","xbrl:period":"2024-12-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"156000000","decimals":-6}]},{"name":"rpt:f-1482","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebt","xbrl:period":"2024-06-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"172830000","decimals":-4}]},{"name":"rpt:f-1483","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | November 30, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 189,698 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 189,698 | \u00a0 |
| Marketable securities | \u00a0 | \u00a0 | 62,551 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 62,551 | \u00a0 |
| Convertible notes receivable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | 935 | \u00a0 | \u00a0 | \u00a0 | 981 | \u00a0 | \u00a0 | \u00a0 | 5,500 | \u00a0 | \u00a0 | \u00a0 | 7,416 | \u00a0 |
| Financial liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Warrant liability | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1,695 | ) | \u00a0 | \u00a0 | (1,695 | ) |
| Contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (15,000 | ) | \u00a0 | \u00a0 | (15,000 | ) |
| APHA 24 Convertible debenture | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total recurring fair value measurements | \u00a0 | $ | 253,184 | \u00a0 | \u00a0 | $ | 981 | \u00a0 | \u00a0 | $ | 20,805 | \u00a0 | \u00a0 | $ | 274,970 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | May 31, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 228,340 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 228,340 | \u00a0 |
| Marketable securities | \u00a0 | \u00a0 | 32,182 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 32,182 | \u00a0 |
| Convertible notes receivable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | 919 | \u00a0 | \u00a0 | \u00a0 | 1,440 | \u00a0 | \u00a0 | \u00a0 | 5,500 | \u00a0 | \u00a0 | \u00a0 | 7,859 | \u00a0 |
| Financial liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Warrant liability | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (3,253 | ) | \u00a0 | \u00a0 | (3,253 | ) |
| Contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (15,000 | ) | \u00a0 | \u00a0 | (15,000 | ) |
| APHA 24 Convertible debenture | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (330 | ) | \u00a0 | \u00a0 | (330 | ) |
| Total recurring fair value measurements | \u00a0 | $ | 261,441 | \u00a0 | \u00a0 | $ | 1,440 | \u00a0 | \u00a0 | $ | 18,917 | \u00a0 | \u00a0 | $ | 281,798 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | APHA 24 | \u00a0 | |
| \u00a0 | \u00a0 | Convertible | \u00a0 | \u00a0 | Equity | \u00a0 | \u00a0 | Warrant | \u00a0 | \u00a0 | Contingent | \u00a0 | \u00a0 | Convertible | \u00a0 | |||||
| \u00a0 | \u00a0 | notes receivable | \u00a0 | \u00a0 | Investments | \u00a0 | \u00a0 | Liability | \u00a0 | \u00a0 | Consideration | \u00a0 | \u00a0 | Debt | \u00a0 | |||||
| Balance, May 31, 2024 | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 5,500 | \u00a0 | \u00a0 | $ | (3,253 | ) | \u00a0 | $ | (15,000 | ) | \u00a0 | $ | (330 | ) |
| Additions/(Repayments) | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 330 | \u00a0 |
| Unrealized gain (loss) on fair value | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 1,558 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Balance, November 30, 2024 | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 5,500 | \u00a0 | \u00a0 | $ | (1,695 | ) | \u00a0 | $ | (15,000 | ) | \u00a0 | $ | \u2014 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | Significant | \u00a0 | \u00a0 | |
| \u00a0 | \u00a0 | Valuation | \u00a0 | unobservable | \u00a0 | \u00a0 | |
| Financial asset / financial liability | \u00a0 | technique | \u00a0 | input | \u00a0 | Inputs | \u00a0 |
| Warrant liability | \u00a0 | Black-Scholes | \u00a0 | Volatility, | \u00a0 | 50% | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | expected life (in years) | \u00a0 | 0.8 | \u00a0 |
| Contingent consideration | \u00a0 | Discounted cash flows | \u00a0 | Discount rate, | \u00a0 | 11% | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | Probability of achievement | \u00a0 |
| \u00a0 |
Note 26. Segment reporting
\n\u00a0
\nInformation reported to the Chief Operating Decision Maker (\u201cCODM\u201d) for the purpose of resource allocation and assessment of segment performance focuses on the nature of the operations. The Company operates in\u00a0 reportable segments:\u00a0(1) beverage\u00a0operations, which encompasses the production, marketing and sale of beverage and beverage\u00a0products, (2) cannabis operations, which encompasses the cultivation, production, distribution,\u00a0sale, co-manufacturing and advisory services of both medical and adult-use cannabis, (3) distribution operations, which encompasses the purchase and resale/distribution of pharmaceuticals products to wholesale and pharmacy customers, and (4) wellness products, which encompasses hemp foods and hemp-derived\u00a0consumer products. This structure is in line with how our Chief Operating Decision Maker (\u201cCODM\u201d) assesses our performance and allocates resources.\u00a0
\n\u00a0
\nOperating segments have not been aggregated and asset information by segment is not disclosed because such information is not reported to or used by the Company\u2019s CODM for purposes of assessing segment performance or allocating resources.
\n\u00a0
\n \n \nSegment gross profit from external customers:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the six months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||||
| Beverage | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net beverage revenue | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 | ||||
| Beverage costs | \u00a0 | \u00a0 | 37,925 | \u00a0 | \u00a0 | \u00a0 | 30,513 | \u00a0 | \u00a0 | \u00a0 | 70,975 | \u00a0 | \u00a0 | \u00a0 | 41,779 | \u00a0 |
| Beverage gross profit | \u00a0 | \u00a0 | 25,156 | \u00a0 | \u00a0 | \u00a0 | 15,992 | \u00a0 | \u00a0 | \u00a0 | 48,078 | \u00a0 | \u00a0 | \u00a0 | 28,888 | \u00a0 |
| Cannabis | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net cannabis revenue | \u00a0 | \u00a0 | 65,652 | \u00a0 | \u00a0 | \u00a0 | 67,114 | \u00a0 | \u00a0 | \u00a0 | 126,901 | \u00a0 | \u00a0 | \u00a0 | 137,447 | \u00a0 |
| Cannabis costs | \u00a0 | \u00a0 | 42,475 | \u00a0 | \u00a0 | \u00a0 | 46,472 | \u00a0 | \u00a0 | \u00a0 | 79,529 | \u00a0 | \u00a0 | \u00a0 | 96,989 | \u00a0 |
| Cannabis gross profit | \u00a0 | \u00a0 | 23,177 | \u00a0 | \u00a0 | \u00a0 | 20,642 | \u00a0 | \u00a0 | \u00a0 | 47,372 | \u00a0 | \u00a0 | \u00a0 | 40,458 | \u00a0 |
| Distribution | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Distribution revenue | \u00a0 | \u00a0 | 67,611 | \u00a0 | \u00a0 | \u00a0 | 67,223 | \u00a0 | \u00a0 | \u00a0 | 135,682 | \u00a0 | \u00a0 | \u00a0 | 136,380 | \u00a0 |
| Distribution costs | \u00a0 | \u00a0 | 59,207 | \u00a0 | \u00a0 | \u00a0 | 60,147 | \u00a0 | \u00a0 | \u00a0 | 119,345 | \u00a0 | \u00a0 | \u00a0 | 121,615 | \u00a0 |
| Distribution gross profit | \u00a0 | \u00a0 | 8,404 | \u00a0 | \u00a0 | \u00a0 | 7,076 | \u00a0 | \u00a0 | \u00a0 | 16,337 | \u00a0 | \u00a0 | \u00a0 | 14,765 | \u00a0 |
| Wellness | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Wellness revenue | \u00a0 | \u00a0 | 14,606 | \u00a0 | \u00a0 | \u00a0 | 12,929 | \u00a0 | \u00a0 | \u00a0 | 29,358 | \u00a0 | \u00a0 | \u00a0 | 26,226 | \u00a0 |
| Wellness costs | \u00a0 | \u00a0 | 10,123 | \u00a0 | \u00a0 | \u00a0 | 9,230 | \u00a0 | \u00a0 | \u00a0 | 20,219 | \u00a0 | \u00a0 | \u00a0 | 18,732 | \u00a0 |
| Wellness gross profit | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 |
\u00a0
\nChannels of Cannabis revenue were as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the six months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||||
| Revenue from Canadian medical cannabis | \u00a0 | $ | 6,673 | \u00a0 | \u00a0 | $ | 6,288 | \u00a0 | \u00a0 | $ | 12,934 | \u00a0 | \u00a0 | $ | 12,430 | \u00a0 |
| Revenue from Canadian adult-use cannabis | \u00a0 | \u00a0 | 59,077 | \u00a0 | \u00a0 | \u00a0 | 72,048 | \u00a0 | \u00a0 | \u00a0 | 116,312 | \u00a0 | \u00a0 | \u00a0 | 143,243 | \u00a0 |
| Revenue from wholesale cannabis | \u00a0 | \u00a0 | 6,593 | \u00a0 | \u00a0 | \u00a0 | 4,289 | \u00a0 | \u00a0 | \u00a0 | 12,100 | \u00a0 | \u00a0 | \u00a0 | 9,584 | \u00a0 |
| Revenue from international cannabis | \u00a0 | \u00a0 | 14,865 | \u00a0 | \u00a0 | \u00a0 | 11,931 | \u00a0 | \u00a0 | \u00a0 | 27,056 | \u00a0 | \u00a0 | \u00a0 | 26,183 | \u00a0 |
| Less excise taxes | \u00a0 | \u00a0 | (21,556 | ) | \u00a0 | \u00a0 | (27,442 | ) | \u00a0 | \u00a0 | (41,501 | ) | \u00a0 | \u00a0 | (53,993 | ) |
| Total | \u00a0 | $ | 65,652 | \u00a0 | \u00a0 | $ | 67,114 | \u00a0 | \u00a0 | $ | 126,901 | \u00a0 | \u00a0 | $ | 137,447 | \u00a0 |
\u00a0
\nThere were advisory services revenue associated with the HEXO commercial transaction agreements for the three and six months ended November 30, 2024. There were and $1,500\u00a0in advisory services revenue associated with the HEXO commercial transaction agreements for the three and six months ended November 30, 2023.
\n\u00a0
\n \n \nGeographic net revenue:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the six months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||||
| USA | \u00a0 | $ | 71,753 | \u00a0 | \u00a0 | $ | 53,374 | \u00a0 | \u00a0 | $ | 135,633 | \u00a0 | \u00a0 | $ | 84,863 | \u00a0 |
| Canada | \u00a0 | \u00a0 | 56,720 | \u00a0 | \u00a0 | \u00a0 | 61,245 | \u00a0 | \u00a0 | \u00a0 | 112,625 | \u00a0 | \u00a0 | \u00a0 | 123,277 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 79,254 | \u00a0 | \u00a0 | \u00a0 | 75,292 | \u00a0 | \u00a0 | \u00a0 | 156,926 | \u00a0 | \u00a0 | \u00a0 | 154,996 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 3,223 | \u00a0 | \u00a0 | \u00a0 | 3,860 | \u00a0 | \u00a0 | \u00a0 | 5,810 | \u00a0 | \u00a0 | \u00a0 | 7,584 | \u00a0 |
| Total | \u00a0 | $ | 210,950 | \u00a0 | \u00a0 | $ | 193,771 | \u00a0 | \u00a0 | $ | 410,994 | \u00a0 | \u00a0 | $ | 370,720 | \u00a0 |
\u00a0
\nGeographic capital assets:
\n\u00a0
\n \n| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| USA | \u00a0 | $ | 200,667 | \u00a0 | \u00a0 | $ | 141,314 | \u00a0 |
| Canada | \u00a0 | \u00a0 | 256,828 | \u00a0 | \u00a0 | \u00a0 | 313,359 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 93,703 | \u00a0 | \u00a0 | \u00a0 | 99,921 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 3,221 | \u00a0 | \u00a0 | \u00a0 | 3,653 | \u00a0 |
| Total | \u00a0 | $ | 554,419 | \u00a0 | \u00a0 | $ | 558,247 | \u00a0 |
\u00a0
\nMajor customers are defined as customers that are materially significant\u00a0to the Company\u2019s annual revenues. For the three and six months ended November 30, 2024 and 2023, there were major customers representing a material contribution\u00a0to\u00a0our quarterly revenues.
\n "}]},{"name":"rpt:f-1579","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-12-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the six months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||||
| Beverage | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net beverage revenue | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 | ||||
| Beverage costs | \u00a0 | \u00a0 | 37,925 | \u00a0 | \u00a0 | \u00a0 | 30,513 | \u00a0 | \u00a0 | \u00a0 | 70,975 | \u00a0 | \u00a0 | \u00a0 | 41,779 | \u00a0 |
| Beverage gross profit | \u00a0 | \u00a0 | 25,156 | \u00a0 | \u00a0 | \u00a0 | 15,992 | \u00a0 | \u00a0 | \u00a0 | 48,078 | \u00a0 | \u00a0 | \u00a0 | 28,888 | \u00a0 |
| Cannabis | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net cannabis revenue | \u00a0 | \u00a0 | 65,652 | \u00a0 | \u00a0 | \u00a0 | 67,114 | \u00a0 | \u00a0 | \u00a0 | 126,901 | \u00a0 | \u00a0 | \u00a0 | 137,447 | \u00a0 |
| Cannabis costs | \u00a0 | \u00a0 | 42,475 | \u00a0 | \u00a0 | \u00a0 | 46,472 | \u00a0 | \u00a0 | \u00a0 | 79,529 | \u00a0 | \u00a0 | \u00a0 | 96,989 | \u00a0 |
| Cannabis gross profit | \u00a0 | \u00a0 | 23,177 | \u00a0 | \u00a0 | \u00a0 | 20,642 | \u00a0 | \u00a0 | \u00a0 | 47,372 | \u00a0 | \u00a0 | \u00a0 | 40,458 | \u00a0 |
| Distribution | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Distribution revenue | \u00a0 | \u00a0 | 67,611 | \u00a0 | \u00a0 | \u00a0 | 67,223 | \u00a0 | \u00a0 | \u00a0 | 135,682 | \u00a0 | \u00a0 | \u00a0 | 136,380 | \u00a0 |
| Distribution costs | \u00a0 | \u00a0 | 59,207 | \u00a0 | \u00a0 | \u00a0 | 60,147 | \u00a0 | \u00a0 | \u00a0 | 119,345 | \u00a0 | \u00a0 | \u00a0 | 121,615 | \u00a0 |
| Distribution gross profit | \u00a0 | \u00a0 | 8,404 | \u00a0 | \u00a0 | \u00a0 | 7,076 | \u00a0 | \u00a0 | \u00a0 | 16,337 | \u00a0 | \u00a0 | \u00a0 | 14,765 | \u00a0 |
| Wellness | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Wellness revenue | \u00a0 | \u00a0 | 14,606 | \u00a0 | \u00a0 | \u00a0 | 12,929 | \u00a0 | \u00a0 | \u00a0 | 29,358 | \u00a0 | \u00a0 | \u00a0 | 26,226 | \u00a0 |
| Wellness costs | \u00a0 | \u00a0 | 10,123 | \u00a0 | \u00a0 | \u00a0 | 9,230 | \u00a0 | \u00a0 | \u00a0 | 20,219 | \u00a0 | \u00a0 | \u00a0 | 18,732 | \u00a0 |
| Wellness gross profit | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 | \u00a0 | $ | \u00a0 |
| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the six months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||||
| Revenue from Canadian medical cannabis | \u00a0 | $ | 6,673 | \u00a0 | \u00a0 | $ | 6,288 | \u00a0 | \u00a0 | $ | 12,934 | \u00a0 | \u00a0 | $ | 12,430 | \u00a0 |
| Revenue from Canadian adult-use cannabis | \u00a0 | \u00a0 | 59,077 | \u00a0 | \u00a0 | \u00a0 | 72,048 | \u00a0 | \u00a0 | \u00a0 | 116,312 | \u00a0 | \u00a0 | \u00a0 | 143,243 | \u00a0 |
| Revenue from wholesale cannabis | \u00a0 | \u00a0 | 6,593 | \u00a0 | \u00a0 | \u00a0 | 4,289 | \u00a0 | \u00a0 | \u00a0 | 12,100 | \u00a0 | \u00a0 | \u00a0 | 9,584 | \u00a0 |
| Revenue from international cannabis | \u00a0 | \u00a0 | 14,865 | \u00a0 | \u00a0 | \u00a0 | 11,931 | \u00a0 | \u00a0 | \u00a0 | 27,056 | \u00a0 | \u00a0 | \u00a0 | 26,183 | \u00a0 |
| Less excise taxes | \u00a0 | \u00a0 | (21,556 | ) | \u00a0 | \u00a0 | (27,442 | ) | \u00a0 | \u00a0 | (41,501 | ) | \u00a0 | \u00a0 | (53,993 | ) |
| Total | \u00a0 | $ | 65,652 | \u00a0 | \u00a0 | $ | 67,114 | \u00a0 | \u00a0 | $ | 126,901 | \u00a0 | \u00a0 | $ | 137,447 | \u00a0 |
| \u00a0 | \u00a0 | For the three months ended | \u00a0 | \u00a0 | For the six months ended | \u00a0 | ||||||||||
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | November 30, | \u00a0 | ||||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||||
| USA | \u00a0 | $ | 71,753 | \u00a0 | \u00a0 | $ | 53,374 | \u00a0 | \u00a0 | $ | 135,633 | \u00a0 | \u00a0 | $ | 84,863 | \u00a0 |
| Canada | \u00a0 | \u00a0 | 56,720 | \u00a0 | \u00a0 | \u00a0 | 61,245 | \u00a0 | \u00a0 | \u00a0 | 112,625 | \u00a0 | \u00a0 | \u00a0 | 123,277 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 79,254 | \u00a0 | \u00a0 | \u00a0 | 75,292 | \u00a0 | \u00a0 | \u00a0 | 156,926 | \u00a0 | \u00a0 | \u00a0 | 154,996 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 3,223 | \u00a0 | \u00a0 | \u00a0 | 3,860 | \u00a0 | \u00a0 | \u00a0 | 5,810 | \u00a0 | \u00a0 | \u00a0 | 7,584 | \u00a0 |
| Total | \u00a0 | $ | 210,950 | \u00a0 | \u00a0 | $ | 193,771 | \u00a0 | \u00a0 | $ | 410,994 | \u00a0 | \u00a0 | $ | 370,720 | \u00a0 |
| \u00a0 | \u00a0 | November 30, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| USA | \u00a0 | $ | 200,667 | \u00a0 | \u00a0 | $ | 141,314 | \u00a0 |
| Canada | \u00a0 | \u00a0 | 256,828 | \u00a0 | \u00a0 | \u00a0 | 313,359 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 93,703 | \u00a0 | \u00a0 | \u00a0 | 99,921 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 3,221 | \u00a0 | \u00a0 | \u00a0 | 3,653 | \u00a0 |
| Total | \u00a0 | $ | 554,419 | \u00a0 | \u00a0 | $ | 558,247 | \u00a0 |
Note 27. Subsequent Events
\n\u00a0
\nFrom\u00a0 December\u00a02, 2024\u00a0to December 11,\u00a02024,\u00a0the Company issued an additional 8,351,253 shares in connection with the Company\u2019s ATM Program, thereby generating gross proceeds of $11,064.\u00a0The Company netted proceeds of after commissions and other fees associated with these issuances in the amount of $221.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1678","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesNewIssues","xbrl:period":"2024-12-02T00:00:00/2024-12-12T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"8351253"}]},{"name":"rpt:f-1679","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromIssuanceOfCommonStock","xbrl:period":"2024-12-02T00:00:00/2024-12-12T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"11064000","decimals":-3}]},{"name":"rpt:f-1680","factDimensions":{"xbrl:concept":"us-gaap:PaymentsOfStockIssuanceCosts","xbrl:period":"2024-12-02T00:00:00/2024-12-12T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"221000","decimals":-3}]}]}}